

DCP3 Series Acknowledgments

Disease Control Priorities, third edition (*DCP3*) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions we convey our acknowledgment and appreciation. First and foremost, we would like to thank our 32 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 170 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network. Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, Damian Walker, and (currently) David Wilson for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for *DCP3* while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington's Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the *DCP3* Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics & Policy; Center for Chronic Disease Control; Centre for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee ensures quality and intellectual rigor of the highest order for *DCP3*.

The National Academies of Science, Engineering, and Medicine, in collaboration with the Interacademy Medical Panel, coordinated the peer-review process for all *DCP3* chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, Rachel Pittluck, and Tara Mainero managed this effort and provided critical and substantive input.

World Bank Publications provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, Mary Fisk, Nancy Lammers, Runit Pancholi, Deborah Naylor, and Sherrie Brown for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that

supported the preparation and dissemination of *DCP3*. We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of noncommunicable diseases (July 2013)
- National Academy of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics & Policy (Quality and Uptake meeting, September 2013, reproductive and maternal health volume consultation, November 2013)
- National Cancer Institute cancer consultation (November 2013)
- Union for International Cancer Control cancer consultation (November 2013, December 2014)
- Harvard T. H. Chan School of Public Health, economic evaluation consultation (September 2015)
- University of California, Berkeley School of Public Health, and Stanford Medical School, occupational and environmental health consultations (December 2015).

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added valuable guidance in applying and improving the extended cost-effectiveness analysis method. Elizabeth Brouwer, Kristen Danforth, Nazila Dabestani, Shane Murphy, Zachary Olson, Jinyuan Qi, and David Watkins provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes, while Jennifer Nguyen, Shamelle Richards, and Jennifer Grasso contributed exceptional project coordination support. The efforts of these individuals were absolutely critical to producing this series, and we are thankful for their commitment.

Volume and Series Editors

VOLUME EDITORS

King K. Holmes

King K. Holmes is the Director of Research and Faculty Development in the University of Washington's Department of Global Health. He also serves as Director of the Center for AIDS Research and Professor in the University of Washington's Department of Medicine, and as Principal Investigator for the University of Washington's International Training and Education Center for Health, with HIV-related programs in 20 countries throughout the world. He served as the William H. Foege Endowed Chair in Health from 2006 to 2015. Holmes has participated in research on sexually transmitted infections (STIs) for over 50 years and in research, training, and technical assistance on HIV/AIDS and other STIs globally for over 30 years.

Stefano Bertozzi

Stefano Bertozzi is Dean and Professor at the School of Public Health at the University of California, Berkeley. He has led impact evaluations of large, national health and social programs in Africa, Asia, Latin America, and Mexico. His research focuses on the prevention of HIV/AIDS and STIs, as well as on risk behavior among adolescents. He was previously the director of the HIV Global Health Program at the Bill & Melinda Gates Foundation. His research has covered a diverse range of projects in health economics and policy, focusing on the economic aspects of HIV/AIDS and the health impact of large social programs.

Barry R. Bloom

Barry R. Bloom is Harvard University Distinguished Service Professor of the Departments of Immunology

and Infectious Diseases and Global Health and Population of the Harvard T. H. Chan School of Public Health, where he served as Dean from 1999 to 2009. His research interests have been in immunology, infectious diseases, tuberculosis, leprosy, and vaccines. He served as a consultant to the White House on international health policy and has been extensively involved with the World Health Organization, chairing advisory committees on tropical diseases, leprosy, tuberculosis, and malaria. He serves as Co-Chair of the Independent Expert Committee of the Human Heredity and Health in Africa (H3Africa) program; is a member of the Scientific Advisory Board of the Africa Health Research Institute in Durban, South Africa; and chairs the Research Advisory Committee of the Public Health Foundation of India.

Prabhat Jha

Prabhat Jha is the founding director of the Centre for Global Health Research at St. Michael's Hospital. He holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is lead investigator of the Million Death Study in India, which quantifies the cause of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

SERIES EDITORS

Dean T. Jamison

Dean T. Jamison is Emeritus Professor in Global Health Sciences at the University of California, San Francisco,

and the University of Washington. He previously held academic appointments at Harvard University and the University of California, Los Angeles. Prior to his academic career, he was an economist on the staff of the World Bank, where he was lead author of the World Bank's *World Development Report 1993: Investing in Health*. He serves as lead editor for *DCP3* and was lead editor for the previous two editions. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the U.S. National Academy of Sciences. He recently served as Co-Chair and Study Director of *The Lancet's* Commission on Investing in Health.

Rachel Nugent

Rachel Nugent is Vice President for Global Non-communicable Diseases at RTI International. She was formerly a Research Associate Professor and Principal Investigator of DCPN in the Department of Global Health at the University of Washington. Previously, she served as Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991–97, she was associate professor and department chair in economics at Pacific Lutheran University.

Hellen Gelband

Hellen Gelband is an independent global health policy expert. Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. She has conducted policy studies at Resources for the Future, the Center for Disease Dynamics, Economics & Policy, the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations.

Susan Horton

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank,

the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others, in work conducted in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as associate provost of graduate studies at the University of Waterloo, vice-president academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto at Scarborough.

Prabhat Jha

See the list of Volume Editors.

Ramanan Laxminarayan

Ramanan Laxminarayan is Director of the Center for Disease Dynamics, Economics & Policy in Washington, DC. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was one of the key architects of the Affordable Medicines Facility—malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

Charles N. Mock

Charles N. Mock, MD, PhD, FACS, has training as both a trauma surgeon and an epidemiologist. He worked as a surgeon in Ghana for four years, including at a rural hospital (Berekum) and at the Kwame Nkrumah University of Science and Technology (Kumasi). In 2005–07, he served as Director of the University of Washington's Harborview Injury Prevention and Research Center. He worked at the WHO headquarters in Geneva from 2007 to 2010, where he was responsible for developing the WHO's trauma care activities. In 2010, he returned to his position as Professor of Surgery (with joint appointments as Professor of Epidemiology and Professor of Global Health) at the University of Washington. His main interests include the spectrum of injury control, especially as it pertains to low- and middle-income countries: surveillance, injury prevention, prehospital care, and hospital-based trauma care. He was President of the International Association for Trauma Surgery and Intensive Care from 2013–15.

Contributors

Elaine J. Abrams

Mailman School of Public Health, Columbia University,
New York, New York, United States

Saeed Ahmed

Baylor College of Medicine–Abbott Fund Children’s
Clinical Center of Excellence, Lilongwe, Malawi

Sevgi O. Aral

Centers for Disease Control and Prevention, Atlanta,
Georgia, United States

Rifat Atun

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Joseph B. Babigumira

Department of Global Health, University of
Washington, Seattle, Washington, United States

Sarah J. Baird

Milken Institute School of Public Health,
The George Washington University,
Washington, DC, United States

Till Bärnighausen

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Fred Newton Binka

University of Health and Allied Sciences, Ho, Ghana

Lori A. Bollinger

Avenir Health, Glastonbury, Connecticut, United States

Donald A. P. Bundy

Bill & Melinda Gates Foundation, London,
United Kingdom

Corey Casper

Fred Hutchinson Cancer Research Center, Seattle,
Washington, United States

Marcia Castro

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Harrell W. Chesson

Centers for Disease Control and Prevention, Atlanta,
Georgia, United States

Justin Cohen

Clinton Health Access Initiative, Boston, Massachusetts,
United States

Myron S. Cohen

University of North Carolina School of Medicine,
Chapel Hill, North Carolina, United States

Ted Cohen

Yale School of Public Health, New Haven, Connecticut,
United States

Chris Cotter

University of California, San Francisco Medical Center,
San Francisco, California, United States

Heidi Crane

Department of Global Health, University of
Washington, Seattle, Washington, United States

John A. Crump

Department of Economics, University of Otago,
Dunedin, New Zealand

Gina Dallabetta

Bill & Melinda Gates Foundation, Seattle, Washington,
United States

Kristen Danforth

Department of Global Health, University of Washington, Seattle, Washington, United States

Lisa M. DeMaria

Berkeley School of Public Health, Berkeley, California, United States

Sake J. de Vlas

Department of Public Health, University Medical Center Rotterdam, the Netherlands

Charlotte Dolenz

Clinton Health Access Initiative, Boston, Massachusetts, United States

Christopher Dye

Office of the Director-General, World Health Organization, Geneva, Switzerland

Wafaa M. El-Sadr

Mailman School of Public Health, Columbia University, New York, New York, United States

Joanne E. Enstone

School of Medicine, University of Nottingham, Nottingham, United Kingdom

Richard Feachem

Global Health Sciences, University of California, San Francisco, San Francisco, California, United States

Christopher Fitzpatrick

Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

Hamish Fraser

Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States

Patricia J. Garcia

Ministry of Health, Lima, Peru

Geoffrey P. Garnett

Bill & Melinda Gates Foundation, Seattle, Washington, United States

Louis P. Garrison Jr.

Department of Global Health, University of Washington, Seattle, Washington, United States

Hellen Gelband

Disease Control Priorities Network, Washington, DC, United States

Gabriela B. Gomez

London School of Hygiene & Tropical Medicine, London, United Kingdom

Roland Gosling

Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California, United States

Reuben Granich

International Association of Providers of AIDS Care, Washington, DC, United States

Simon A. J. Gregson

Biomedical Research and Training Institute, Harare, Zimbabwe

Timothy B. Hallett

School of Public Health, Imperial College London, London, United Kingdom

James R. Hargreaves

London School of Hygiene & Tropical Medicine, London, United Kingdom

Katherine Harripersaud

Mailman School of Public Health, Columbia University, New York, New York, United States

Kate L. Harris

Bill & Melinda Gates Foundation, Seattle, Washington, United States

Bernadette Hensen

London School of Hygiene & Tropical Medicine, London, United Kingdom

Charles B. Holmes

Centre for Infectious Disease Research, Lusaka, Zambia

Susan Horton

School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada

Grace John-Stewart

Department of Global Health, University of Washington, Seattle, Washington, United States

James G. Kahn

Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, California, United States

John Kinuthia

Kenyatta National Hospital, Nairobi, Kenya

Gwen Knight

London School of Hygiene & Tropical Medicine, London, United Kingdom

Shari Krishnaratne

London School of Hygiene & Tropical Medicine, London, United Kingdom

Advisory Committee to the Editors

Anne Mills, Chair

Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi

Director, Health, Nutrition and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu

Minister of Health, Addis Ababa, Ethiopia

George Alleyne

Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan

Regional Director Emeritus, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun

Professor, Global Health Systems, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Zulfiqar Bhutta

Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho

Former Minister of Health, Kigali, Rwanda

Mark Blecher

Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia

Minister of Health, Lima, Peru

Roger Glass

Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman

Chief Operating Officer and Senior Fellow, Center for Global Development, Washington, DC, United States

Glenda Gray

Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte

Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton

Editor, *The Lancet*, London, United Kingdom

Edward Kirumira

Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann

Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi

Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud

Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham

World Bank (retired)

Carol Medlin

Independent Consultant, Washington, DC, United States

Alvaro Moncayo

Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya

Executive Director, Philippine Council for Health Research and Development, Taguig City, the Philippines

Ole Norheim

Professor, Department of Global Health and Primary Care, University of Bergen, Bergen, Norway

Folashade Omokhodion

Professor, University College Hospital, Ibadan, Nigeria

Toby Ord

President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy

President, Public Health Foundation of India, New Delhi, India

Sevket Ruacan

Dean, Koç University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda

Executive Director, Global Health Sciences, University of California, San Francisco, California, United States

Richard Skolnik

Yale University School of Public Health (retired)

Stephen Tollman

Professor, University of Witwatersrand, Johannesburg, South Africa

Jürgen Unutzer

Professor, Department of Psychiatry, University of Washington, Seattle, Washington, United States

Damian Walker

Deputy Director of Data and Analytics, Bill & Melinda Gates Foundation, Seattle, Washington, United States

Ngaire Woods

Director, Global Economic Governance Program, Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai

Professor, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand

Kun Zhao

Researcher, China National Health Development Research Center, Beijing, China

Ramanan Laxminarayan

Center for Disease Dynamics, Economics & Policy,
Washington, DC, United States

Christian Lengeler

Swiss Tropical and Public Health Institute, Basel,
Switzerland

Edeltraud Lenk

Erasmus University Rotterdam, Rotterdam, the
Netherlands

Carol Levin

Department of Global Health, University of
Washington, Seattle, Washington, United States

Jenny Liu

Global Health Sciences, University of California, San
Francisco, San Francisco, California, United States

Yoel Lubell

Mahidol Oxford Tropical Medicine Research Unit,
Bangkok, Thailand

David Mabey

London School of Hygiene & Tropical Medicine,
London, United Kingdom

Kudzai Makomva

Malaria Elimination 8 Secretariat, Windhoek, Namibia

Elliot Marseille

Health Strategies International, San Francisco,
California, United States

Philippe Mayaud

London School of Hygiene & Tropical Medicine,
London, United Kingdom

Margaret McNairy

Weill Cornell Medical College, Cornell University,
Ithaca, New York, United States

Didier Ménard

Worldwide Antimalarial Resistance Network,
Paris, France

Molly Miller-Petrie

Center for Disease Dynamics, Economics & Policy,
Washington, DC, United States

Deborah Money

Department of Obstetrics & Gynecology, University
of British Columbia, Vancouver, British Columbia,
Canada

Meghan Murray

Harvard T.H. Chan School of Public Health, Boston,
Massachusetts, United States

Edward Nardell

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Gretchen Newby

Global Health Sciences, University of California,
San Francisco, San Francisco, California,
United States

Paul N. Newton

Lao-Oxford-Mahosot Hospital, Wellcome Trust
Research Unit, Vientiane, the Lao People's Democratic
Republic

Uzoma Nwankwo

Federal Ministry of Health of Nigeria, Abuja, Nigeria

Nancy Padian

Berkeley School of Public Health, University of
California, Berkeley, California, United States

Rosanna W. Peeling

International Diagnostics Centre, London School
of Hygiene & Tropical Medicine, London,
United Kingdom

Allison Phillips

Global Health Sciences, University of California, San
Francisco, San Francisco, California, United States

Yogan Pillay

South African National Department of Health, Pretoria,
South Africa

Suraj Pant

Center for Disease Dynamics, Economics & Policy,
Washington, DC, United States

Paul Revill

Centre for Health Economics, University of York, York,
United Kingdom

Eric Rubin

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Joshua Salomon

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Michael Santos

Bill & Melinda Gates Foundation, Seattle, Washington,
United States

Rima Shretta

Global Health Sciences, University of California, San
Francisco, San Francisco, California, United States

John Stover

Avenir Health, Glastonbury, Connecticut, United States

Jessica Taaffe

World Bank, Washington, DC, United States

Marcel Tanner

Swiss Tropical and Public Health Institute, Basel, Switzerland

Allison Tatarsky

Clinton Health Access Initiative, Boston, Massachusetts, United States

Fabrizio Tediosi

Swiss Tropical and Public Health Institute, Basel, Switzerland

Harsha Thirumurthy

Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, United States

Anna Vassal

London School of Hygiene & Tropical Medicine, London, United Kingdom

Grigory Volchenkov

Vladimir Oblast Tuberculosis Dispensary, Center of Excellence for Tuberculosis Infection Control, Vladimir, the Russian Federation

Rochelle P. Walensky

Harvard Medical School, Boston, Massachusetts, United States

Tim Wells

Medicines for Malaria Venture, Geneva, Switzerland

Richard White

London School of Hygiene & Tropical Medicine, London, United Kingdom

Danielle Wideman

Berkeley School of Public Health, University of California, Berkeley, California, United States

Stefan Z. Wiktor

Department of Global Health, University of Washington, Seattle, Washington, United States

David Wilson

World Bank, Washington, DC, United States

Douglas Wilson

Department of Medicine, Edendale Hospital, KwaZulu-Natal, South Africa

Prashant Yadav

William Davidson Institute, University of Michigan, Ann Arbor, Michigan, United States

Reviewers

Leela Barham

Economic Consulting LTD, Royston, United Kingdom

Zulfqar A. Bhutta

Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Richard E. Chaisson

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States

Arantxa Colchero

Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico

James Curran

Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Helen Fletcher

Tuberculosis Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom

Omar Galárraga

Brown University School of Public Health, Providence, Rhode Island, United States

Glenda Gray

Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Laura A. Guay

Milken Institute School of Public Health, George Washington University, Washington, DC, United States

Kristian Schultz Hansen

Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, United Kingdom

Cecilia T. Hugo

ACTMalaria, Manila, the Philippines

Salim S. Abdool Karim

Centre for the AIDS Programme of Research in South Africa (CAPRISA), Columbia University, Durban, South Africa

Michael Lynch

Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Kamini Mendis

Independent Consultant, Colombo, Sri Lanka

Praphan Phanuphak

Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Anthony Seddoh

Health, Nutrition and Population Global Practice, World Bank, Accra, Ghana

Laurence Slutsker

Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Samuel So

Asian Liver Center, Stanford University School of Medicine, Palo Alto, California, United States

Sunil Suhas Solomon

Johns Hopkins University School of Medicine,
Baltimore, Maryland, United States

Neeraj Sood

Sol Price School of Public Policy and Schaeffer Center
for Health Policy and Economics, University of Southern
California, Los Angeles, California, United States

Paul Volberding

AIDS Research Institute, University of California, San
Francisco, San Francisco, California, United States

Diana Weil

Global TB Programme, World Health Organization,
Geneva, Switzerland

Mary E. Wilson

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Index

Boxes, figures, maps, notes, and tables are indicated by *b*, *f*, *m*, *n*, and *t* following the page number.

A

- Abrams, Elaine J., 67
- Abu-Raddad, L. J., 283
- Acinetobacter* spp., 366
- ADCs (AIDS-defining cancers), 45, 46
- adherence to treatment
 - HIV/AIDS, 79–81
 - barriers, 79–80
 - cost-effectiveness, 81
 - decentralized care and, 81
 - guidelines, 79
 - improvement approaches, 80–81
 - measurement of, 79
 - mother-to-child transmission (MTCT), 122
 - peer counseling and, 81
 - rationale and coverage, 79
 - tuberculosis, 274–75
- adolescents. *See also* children
 - febrile illness among, 365–84
 - burden of, 365–66
 - cost-effectiveness of interventions, 374–79, 376–77*f*
 - costs of, 373, 374*f*
 - diagnosis, 369, 370–71*t*, 372–73, 378
 - at district hospital facilities, 371–72
 - etiology of, 366
 - at first-level health facilities, 371
 - future research needs, 377–79
 - incidence rates, 366–68, 368–69*t*
 - sepsis management and, 375
 - surveillance, 375
 - treatment interventions, 370–71*t*, 371–72
 - HIV/AIDS among, 8, 38
 - adherence to treatment, 80
 - testing services, 68, 69
- AEM. *See* AIDS Epidemic Model
- Afghanistan, cutaneous leishmaniasis in, 422
- Africa. *See also specific countries and regions*
 - febrile illness in, 366
 - hepatitis in, 404
 - malaria control in, 348
 - tuberculosis incidence rates, 240
- Africa Centre, 104*b*
- African Americans
 - dyslipidemia among, 55
 - as HIV/AIDS key population, 36–37
- African Leaders Malaria Alliance, 316
- Agence Nationale de Recherche, 104*b*
- agricultural usage of antibiotics, 438, 439*f*, 441–42, 442*t*
- Ahmed, Saeed, 67
- AIDS-defining cancers (ADCs), 45, 46
- AIDS Epidemic Model (AEM), 180, 181–85*t*, 186, 192, 196–97
- AIDS Impact Model (AIM), 186, 187
- Alam, N., 214
- Alistar, S. S., 97
- Ambinder, R. F., 47
- amikacin, 252, 253
- anal cancer, 45
- anal sex, 207
- Anderson, S., 35, 36
- Angola, malaria elimination in, 321*b*
- antibiotics and antimicrobial resistance, 19–20, 433–48
 - drivers of use, 19, 435–39, 437*m*

- food animal production usage, 438, 439*f*, 441–42, 442*t*
 - health care usage, 435–38
 - hospital usage, 438, 438*f*, 441
 - interventions to ensure appropriate use, 19–20, 439–43
 - agricultural usage regulations, 438, 439*f*, 441–42, 442*t*
 - education and awareness campaigns, 441–42
 - in hospitals, 441
 - incentives, 441
 - surveillance, 442–43
 - vaccinations, 440–41
 - water, sanitation, and hygiene, 439–40
 - sexually transmitted infections and, 208
 - antiretroviral treatment (ART), 5
 - cardiovascular disease and, 53
 - effectiveness of, 91
 - mortality rates and, 208
 - mother-to-child transmission (MTCT) and, 91, 121, 122
 - for persons who inject drugs (PWIDs), 163
 - preexposure prophylaxis (PrEP) and, 93
 - resource allocation modeling and, 197, 198
 - transmission biology and, 92
 - tuberculosis treatment and, 253–54
 - Arab Republic of Egypt. *See* Egypt, Arab Republic of
 - Aral, Sevgi O., 203, 222, 223
 - Argentina, malaria elimination in, 315
 - Armenia, malaria elimination in, 315
 - ART. *See* antiretroviral treatment
 - artemisinin-based combination therapies (ACTs), 318, 327–28, 385
 - artemisinin resistance, 322–24, 323*m*
 - ascariasis, 416
 - Asia Pacific Leaders Malaria Alliance, 316
 - Attia, S., 93
 - Atun, Rifat, 233, 235
 - Australia
 - hepatitis in, 407
 - HIV/AIDS in
 - localized intervention programs, 163
 - men who have sex with men (MSM), 163
 - treatment as prevention (TasP), 94
 - sexually transmitted infections in, 214
 - tuberculosis interventions in, 280
 - autopsy procedures, 366
 - Avahan Program, 148, 163, 216
 - Avenir Health models, 146, 180, 181–85*t*, 186–90
 - Azerbaijan, malaria elimination in, 315, 321*b*
 - azithromycin, 216, 420, 421, 422
- B**
- Babigumira, Joseph B., 385
 - bacille Calmette–Guérin (BCG) vaccine, 233, 243, 255–56, 278, 279
 - bacterial sepsis, 375
 - bacterial vaginosis, 46, 52, 145
 - Baggaley, R. F., 222
 - Baird, Sarah J., 365, 375
 - Bangladesh
 - resource allocation modeling in, 197
 - sexually transmitted infections in, 214, 215
 - tuberculosis in
 - community-based care, 266
 - diagnosis, 263*b*
 - hospital-based care in, 264
 - information management system, 275
 - research and development, 283
 - typhoid in, 373
 - vector control interventions in, 419
 - visceral leishmaniasis in, 19, 415
 - Bärnighausen, T., 97
 - Baxi, Sanjiv, 29
 - Baxter, C., 214
 - BCG. *See* bacille Calmette–Guérin vaccine
 - bedaquiline, 251, 253, 277, 284
 - behavioral change
 - HIV/AIDS, 49
 - sexually transmitted infections and, 8, 207, 210, 219
 - behavioral economics, 198–99
 - Belarus, HIV/AIDS in, 171, 171*f*
 - Bendavid, E., 97
 - Benin
 - HIV/AIDS testing services in, 70
 - sexually transmitted infections in, 216
 - Bertozzi, Stefano, 1
 - Bill & Melinda Gates Foundation, 148, 163, 187, 198, 280, 348, 349
 - Bingham, A. L., 223
 - bisexual persons. *See* lesbian, gay, bisexual, and transgender (LGBT) persons
 - Blacksell, S. D., 367
 - Blaya, J. A., 273
 - blood supply safety, 16, 405
 - Bloom, Barry R., 1, 11, 233
 - Bloom, D. E., 97
 - Blower, S., 95
 - Bollinger, Lori A., 148, 179, 188
 - Borghi, J., 221
 - Botswana
 - HIV/AIDS in
 - cardiovascular disease comorbidity, 53

- morbidity rates, 33
 - mother-to-child transmission, 125
 - treatment as prevention (TasP), 104*b*
 - malaria elimination in, 321*b*
 - Boyd, M. F., 337
 - Brandeau, M. L., 97
 - Brazil
 - antibiotic use in, 438
 - febrile illness in, 386
 - hepatitis treatment access in, 405
 - HIV/AIDS in
 - dyslipidemia comorbidity, 56
 - incidence rates, 35
 - syphilis in, 130
 - tuberculosis in
 - diagnosis, 263
 - pharmaceutical supply chain, 272
 - preventive therapy, 257
 - research and development, 283
 - brucellosis, 367, 368
 - Brunei Darussalam, malaria in, 318
 - Bundy, Donald A. P., 411
 - burden of disease
 - antiretroviral treatment (ART) and, 208
 - Burkholderia pseudomallei*, 373
 - cardiovascular disease, 52–53
 - chlamydia, 7, 207
 - by country income group, 2, 2*t*
 - dengue, 413, 413*t*, 414–15
 - diabetes mellitus, 54
 - dyslipidemia, 55
 - febrile illness, 365–66, 397, 397*t*
 - gonorrhea, 7, 207
 - hepatitis, 16, 402, 403*f*, 403*m*
 - herpes simplex virus (HSV-1 and HSV-2), 207
 - HIV/AIDS, 31–33, 31–33*f*, 31*f*, 32–33
 - comorbidities, 45–66
 - mother-to-child transmission (MTCT), 114–19, 114*t*, 116–19*m*
 - human African trypanosomiasis (HAT), 416
 - human papillomavirus (HPV), 7, 207
 - leptospirosis, 373
 - malaria, 316, 348, 373, 413, 413*t*
 - meliodosis, 373
 - neglected tropical diseases (NTDs), 19, 412–15, 413–14*t*, 414*f*
 - Orientia tsutsugamushi*, 373
 - schistosomiasis, 416
 - sexually transmitted infections, 7–8, 204–7
 - syphilis, 7, 114–19, 114*t*, 116–19*m*, 207
 - trichomoniasis, 7, 207
 - tuberculosis, 234, 237–42, 238–39*t*, 244
 - typhoid, 373
 - visceral leishmaniasis, 416
 - WHO estimates on, 380*n1*
 - Burkholderia pseudomallei*, 373
 - Burkina Faso, HIV/AIDS in, 159
 - Burnet Institute, 180
 - Buruli ulcer, 18, 414, 419
- C**
- CAESAR (Central Asian and Eastern European Surveillance of Antimicrobial Resistance), 443
 - Cambodia
 - dengue in, 414–15
 - febrile illness in, 367
 - malaria in
 - incidence rates, 316
 - interventions, 321*b*
 - sexually transmitted infections in, 221
 - tuberculosis diagnosis in, 262
 - Cameroon
 - Buruli ulcer in, 414
 - HIV/AIDS in
 - dyslipidemia comorbidity, 55, 56
 - testing services, 70
 - sexually transmitted infections in, 215
 - Canada
 - antimicrobial resistance in, 440
 - HIV/AIDS in, 95
 - malaria elimination in, 326
 - sexually transmitted infections in, 203, 214
 - tuberculosis in, 280
 - cancer
 - HIV/AIDS comorbidity, 46–50
 - anal cancer, 48
 - behavioral interventions, 49
 - cervical cancer, 47
 - chemoprevention of, 49
 - epidemiology of, 46–47
 - hepatocellular carcinoma (HCC), 48
 - Kaposi sarcoma (KS), 47
 - lung cancer, 48
 - lymphoma, 47–48
 - pathogenesis of HIV-associated malignancies, 47
 - prevention strategies, 48–49
 - screening for, 49
 - vaccines and, 48–49
 - Canchihuaman, F. A., 9
 - Candida* spp., 367
 - carbamazepine, 253

- cardiovascular disease and HIV/AIDS comorbidity, 52–54
 - ART impact on, 53
 - burden of, 52–53
 - epidemiology of, 52–53
 - factors associated with, 53
- Caribbean. *See* Latin America and Caribbean
- Carrara, V., 221
- Casper, Corey, 45, 47
- Castellsague, X., 210
- Castro, Marcia, 347
- Cates, W., 144
- CBT (community-based testing), 69
- Celli, Angelo, 352
- Center for Disease Dynamics, 439
- Centers for Disease Control and Prevention (CDC), 24n1, 30, 75, 433
- Central African Republic, syphilis in, 203
- Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR), 443
- cephalosporins, 208
- cervical cancer
 - HIV/AIDS comorbidity, 45, 46, 47
 - HPV and, 205
 - incidence rates, 7
 - screening for, 49
- Chagas disease
 - cost-effectiveness of interventions, 421
 - interventions for, 18, 414
 - mortality and morbidity rates, 413, 413t, 416
 - vector control interventions, 418–19, 424, 427
 - vector transmission prevention, 421
- Chambers, R., 334
- Charania, M. R., 217
- Chersich, M., 215
- Chesson, Harrell W., 203, 223
- chikungunya, 366, 367, 419, 421
- children. *See also* mother-to-child transmission (MTCT)
 - febrile illness among, 385–400
 - costs of treatment, 394, 395–96t
 - decision-analytic model for, 388–90, 388–89f
 - diagnosis, 394, 395–96t
 - mortality rates, 397, 397t
 - study methodology, 386–94, 387t, 391–94t
 - hepatitis vaccinations for, 404, 406
 - HIV/AIDS among
 - adherence to treatment, 79, 80
 - linkage to care and treatment, 75, 76
 - retention in care, 78
 - testing services, 68, 69
 - malaria among, 322, 348
 - sexually transmitted infections among, 205
 - tuberculosis among
 - comorbidities, 245
 - vaccinations, 255–56
- China
 - antibiotic resistance in, 433, 434f, 441, 442
 - antibiotic use in, 438
 - febrile illness in, 367
 - hepatitis in
 - cost-effectiveness of interventions, 407
 - vaccinations, 404, 406
 - HIV/AIDS in
 - burden of, 116
 - mother-to-child transmission, 130
 - testing services, 70
 - treatment as prevention (TasP), 93, 164
 - malaria elimination in, 321b, 328–29
 - malaria incidence rates in, 318
 - syphilis in, 129, 130
 - tuberculosis in
 - diagnosis, 250
 - incidence rates, 240
 - pharmaceutical supply chain, 272
 - treatment interventions, 254
- chlamydia
 - burden of, 7, 207
 - incidence rates, 203
 - male circumcision and, 210
- Chlamydia trachomatis*, 418
- chloroquine (CQ), 350, 385
- cholesterol, 55
- CHWs (community health workers), 76
- circumcision. *See* voluntary male medical circumcision (VMMC)
- clofazamine, 253
- Clostridium difficile*, 433, 437, 440
- Cochrane Library, 193, 210
- Cohen, Justin, 315
- Cohen, Ted, 233
- Coker, R., 235
- Colombia
 - Chagas disease in, 421
 - sexually transmitted infections in, 219
- Commission on AIDS in Asia, 197
- Commission on Macroeconomics and Health, 199
- community-based interventions
 - HIV/AIDS, 163
 - mother-to-child transmission (MTCT), 124
 - testing services, 70, 75
 - sexually transmitted infections, 216–17, 221–22
 - tuberculosis, 264–69, 266f, 267t
 - efficiency and effectiveness of, 265–66, 267t
 - human resource challenges to, 267
 - private sector challenges, 267–68

- recommendations, 292
 - targeting, 268–69
 - community-based testing (CBT), 69
 - community health workers (CHWs), 76
 - comorbidities
 - HIV/AIDS, 45–66
 - bacterial vaginosis, 52
 - cancer, 46–50
 - cardiovascular disease, 52–54
 - diabetes mellitus, 54–55
 - dyslipidemia, 55–57, 55*t*
 - febrile illness, 368, 368*t*, 372
 - female reproductive health, 50–51
 - hepatitis C, 198
 - herpes simplex virus, 51
 - human papillomavirus (HPV), 51
 - malaria, 348
 - noncommunicable chronic comorbidities (NCCs), 52–57
 - other sexually transmitted infections, 51–52, 115
 - pelvic inflammatory disease, 51–52
 - sexually transmitted intestinal and enteric infections, 52
 - tuberculosis, 234, 239, 245
 - infection control and, 3
 - concentrated HIV/AIDS epidemics, 158, 159–60, 159–60*f*
 - condom use
 - HIV/AIDS and, 50, 137, 143–44, 161, 163
 - resource allocation modeling and, 198
 - sexually transmitted infection prevention via, 210
 - Copenhagen Consensus Center, 280
 - cost. *See also* cost-effectiveness of interventions
 - of febrile illness, 373, 374*f*, 394, 395–96*t*
 - of hepatitis, 406–7, 406*t*
 - of HIV/AIDS
 - prevention interventions, 146–50, 148*t*, 149–50*f*
 - retention in care, 78–79
 - of malaria control interventions, 350–51
 - of neglected tropical diseases (NTDs) treatment interventions, 420–22, 420*t*
 - Costa Rica, malaria elimination in, 315
 - cost-effectiveness of interventions
 - dengue, 421
 - febrile illness, 374–77, 376–77*f*, 378–79
 - hepatitis, 406–7, 406*t*
 - HIV/AIDS, 76–77, 81
 - local epidemics, 170–73, 171–73*f*, 172*t*
 - mother-to-child transmission (MTCT), 125–29, 126–27*t*, 126*f*
 - prevention, 137–56
 - retention in care, 78–79
 - testing services, 70–75, 71–74*t*
 - human African trypanosomiasis (HAT), 422
 - malaria control, 350–51
 - neglected tropical diseases (NTDs) treatment interventions, 420–22, 420*t*
 - point-of-care tests (POCTs), 378
 - preexposure prophylaxis (PrEP), 137, 149
 - sexually transmitted infection interventions, 217–22, 218–19*t*
 - syphilis, mother-to-child transmission (MTCT), 125–29, 126*f*, 128–29*t*
 - treatment as prevention (TasP), 96–102, 98–99*t*
 - treatment interventions, 20–22, 21*f*
 - tuberculosis, 281–89, 285–86*t*, 288*f*
 - vaccines and vaccinations, 20
 - visceral leishmaniasis, 374, 422
 - yaws, 422
 - Côte d’Ivoire
 - HIV/AIDS in, 78–79
 - malaria elimination in, 334
 - soil-transmitted helminthiasis in, 421
 - syphilis in, 203
 - tuberculosis in, 257
 - cotrimoxazole, 254
 - Cotter, Chris, 315
 - Crane, Heidi, 45
 - Crump, John A., 365, 366, 375
 - Cryptococcus* spp., 367
 - Cuba, HIV/AIDS in, 114, 125
 - cutaneous leishmaniasis, 18, 421–22
 - cysticercosis, 2
- D**
- DAA. *See* direct acting antiviral medicines
 - Dallabetta, Gina, 137
 - DALYs
 - febrile illness, 366, 376, 378, 386
 - HIV/AIDS, 33–34
 - prevention interventions, 149, 151
 - treatment as prevention (TasP), 96
 - malaria, 351
 - neglected tropical diseases and, 413, 421, 423, 425, 427
 - resource allocation modeling and, 180, 199
 - sexually transmitted infections and, 8, 205, 208, 221
 - syphilis and, 129
 - tuberculosis, 284
 - Danforth, Kristen, 29
 - Database of Abstracts of Reviews of Effects, 210
 - Davis, K. R., 144
 - Decision Makers’ Program Planning Tool (DMPPT)
 - model, 189–90, 196
 - Deen, J., 367
 - delamanid, 251, 253, 277

- DeMaria, Lisa M., 1
- Democratic Republic of Congo
 antibiotic resistance in, 433, 434*f*
 human African trypanosomiasis in, 415, 422
 malaria control in, 348, 359
 malaria mortality rates in, 316
 tuberculosis in, 264
- Demographic and Health Surveys, 39
- DemProj, 186
- dengue
 burden of, 414–15
 community-based care, 376
 cost-effectiveness of interventions, 421
 diagnosis, 372
 incidence rates, 365, 367, 368
 mortality and morbidity rates, 413, 413*t*
 vector control interventions, 419, 424, 427
 vector transmission prevention, 421
- de Vlas, Sake J., 215, 411
- diabetes mellitus
 febrile illness comorbidity, 368, 368*t*
 HIV/AIDS comorbidity, 54–55
 burden of, 54
 epidemiology of, 54
 factors associated with, 54–55
 as tuberculosis risk factor, 246–47
- diagnosis
 dengue, 372
 febrile illness, 369, 370–71*t*, 372–73, 378, 394, 395–96*t*
 malaria, 327–29, 350
 sexually transmitted infections, 206
 tuberculosis, 248–50, 249*b*, 261–64, 263*b*, 292
 typhoid, 369
- diarrhea, 366, 378
- Digbeu, N., 214
- diphtheria, 22
- direct acting antiviral (DAA) medicines, 401, 405, 407
- Djibouti, malaria in, 316
- Dolenz, Charlotte, 315
- Dominican Republic
 HIV/AIDS in, 160
 malaria elimination in, 331
 sexually transmitted infections in
 community-based interventions, 221
 structural interventions, 217
- DOTS strategy, 234, 240–41, 240*b*, 254, 291–92
- Dowdy, D. W., 283
- doxycycline, 375, 376
- dracunculiasis (Guinea worm), 415
- drug interventions. *See also* antibiotics and antimicrobial resistance; vaccines and vaccinations; *specific medications*
 malaria, 353–56, 354–55*f*
 long-term chemoprotection via, 355–56
 transmission-blocking medicines, 355
 mass drug administration (MDA), 327–28
 neglected tropical diseases (NTDs), 18, 416–18, 420, 420*t*
 sexually transmitted infections, 9
 treatment as prevention (TasP), 103–4
 tuberculosis
 drug toxicities and interactions, 253
 research and development, 275–80
- Dua, V., 333
- Dye, Christopher, 233, 241
- dyslipidemia, 55–57, 55*t*
- E**
- East Africa, HIV/AIDS in. *See also specific countries*
 comorbidities in, 47
 incidence rates in, 33, 35
 testing services in, 70
- East Asia and Pacific. *See also specific countries*
 hepatitis in
 incidence rates, 16
 mortality rates, 401
 HIV/AIDS in
 comorbidities, 46
 concentrated epidemics, 159
 incidence rates, 33
 key populations, 37
 malaria elimination in, 332
- Eastern Europe and Central Asia. *See also specific countries*
 antibiotic use in, 443
 hepatitis in
 incidence rates, 16
 prevalence, 401
 HIV/AIDS in
 allocative efficiency for interventions, 173, 173*f*
 incidence rates, 33
 key populations, 36
 morbidity rates, 33
- East-West Center, 180
- Eaton, J. W., 95–96, 97, 101
- Ebola, 2, 8, 22, 206, 287
- eChasqui, 273
- ectopic pregnancies, 51
- efavirenz, 253
- Egypt, Arab Republic of
 hepatitis in
 incidence rates, 16
 prevalence, 401–2
 malaria elimination in, 315
- electronic medical records (EMRs), 273–74

- El-Sadr, Wafaa M., 67
- El Salvador, syphilis in, 203
- Embase, 210
- End TB Strategy, 235, 291
- Enstone, Joanne E., 137
- enteritis, 52
- enzyme-linked immunosorbent assay (ELISA) test, 119, 131n5
- Epidemiological Modeling (EMOD), 180, 181–85t, 186, 192
- Epstein-Barr virus, 47
- Eritrea
 - HIV/AIDS morbidity rates in, 33
 - tuberculosis incidence rates in, 240
- Escherichia coli*, 366, 367, 435, 436b, 440
- Estonia
 - tuberculosis diagnosis in, 249
 - tuberculosis treatment in, 264
- ethambutol, 251, 253
- Ethiopia
 - antimicrobial resistance in, 439
 - HIV/AIDS in
 - dyslipidemia comorbidity, 56
 - morbidity rates, 33
 - trichiasis in, 413–14
 - tuberculosis treatment in, 264
- European Medicines Agency, 329, 356
- F**
- Family Health International, 187
- family planning, 124
- FamPlan model, 186
- Feachem, Richard, 315
- febrile illness, 365–400
 - in adolescents and adults, 365–84
 - burden of, 365–66
 - cost-effectiveness of interventions, 374–79, 376–77f
 - costs of, 373, 374f
 - diagnosis, 369, 370–71t, 372–73, 378
 - at district hospital facilities, 371–72
 - etiology of, 366
 - at first-level health facilities, 371
 - future research needs, 377–79
 - incidence rates, 366–68, 368–69t
 - sepsis management and, 375
 - surveillance, 375
 - treatment interventions, 370–71t, 371–72
 - in children, 385–400
 - costs of treatment, 394, 395–96t
 - decision-analytic model for, 388–90, 388–89f
 - diagnosis, 394, 395–96t
 - mortality rates, 397, 397t
 - study methodology, 386–94, 387t, 391–94t
 - HIV/AIDS comorbidity, 368, 368t, 372
 - intervention packages, 14, 14–15t, 370–71t, 371–72
- Federal Drug Administration (FDA, U.S.), 276
- financing
 - in health system framework, 235f, 236
 - malaria elimination and eradication, 330–36, 331t, 333–35f, 335–36b
 - tuberculosis intervention programs, 280–81, 280–81f, 289–90, 290t
- Fitzpatrick, Christopher, 411
- fluoroquinolone, 276
- Fofana, O., 283
- Fontanet, A. L., 210
- food animal production, antibiotic usage in, 438, 439f, 441–42, 442t
- France, tuberculosis intervention financing in, 280
- Fraser, Hamish, 233
- Fraser, N., 95
- Frenk, J., 235
- Furness, B. W., 208
- Futures Institute, 186
- G**
- Galárraga, O., 146
- Galeo, S., 289
- Gallup, J. L., 333
- Gandhi, N. R., 259
- Gantt, S., 47
- Garcia, Patricia J., 113
- Garnett, Geoff P., 137
- Garrison, Louis P., Jr., 385
- Gates, B., 334
- Gavi, the Vaccine Alliance, 24n10, 190, 220
- gay persons. *See* lesbian, gay, bisexual, and transgender (LGBT) persons
- GBD. *See* Global Burden of Disease
- Gelband, Hellen, 1, 385
- generalized HIV/AIDS epidemics, 158, 160–61
- GeneXpert, 272, 282
- Geng, E. H., 39
- geographic targeting, 167–70, 168–70m, 169f
- Georgia, malaria elimination in, 315
- Germany, tuberculosis intervention financing in, 280
- Ghana
 - Buruli ulcer in, 414
 - febrile illness in, 386
 - HIV/AIDS in
 - concentrated epidemics, 160
 - men who have sex with men (MSM), 160
 - malaria elimination in, 12, 333
 - sexually transmitted infections in, 216
- GHD. *See* Global Health Decisions model

- Glaxo-Smith-Kline, 104, 356
- Global Action Plan on Antimicrobial Resistance, 439
- Global Antibiotic Resistance Partnership, 443
- Global Burden of Disease (GBD), 8, 33, 425. *See also* burden of disease
- Global Drug Facility, 270
- Global Fund to Fight AIDS, Tuberculosis, and Malaria
on HIV/AIDS interventions, 20, 138, 190, 196
on malaria interventions, 318, 335, 349
on tuberculosis interventions, 240, 280
- Global Health Cost Consortium, 198
- Global Health Decisions (GHD) model, 180, 181–85*t*, 186, 192–93
- Global Health Estimates database, 380n1
- Global Health Observatory Data Repository, 203
- Global Health Workforce Alliance, 190
- Global Laboratory Initiative, 240
- Global Malaria Action Plan (GMAP), 348, 349, 350
- Global Malaria Eradication Program (GMEP), 318, 320, 330–31
- Global Plan to Stop TB, 241, 258
- Global Resource Needs Estimate (GRNE) model, 187, 196
- glucocorticoids, 253
- Goals model, 180, 181–85*t*, 188–89, 189*f*
- Golden, M. R., 215
- Goldie, S. J., 220
- Goldmann, E., 289
- Gomez, Gabriela B., 114–15, 233
- gonococcal antimicrobial resistance, 208
- gonorrhoea
antimicrobial resistance and, 208
burden of, 7, 207
incidence rates, 203
income inequality and, 223
- Gosling, Roly, 315
- governance in health system framework, 235*f*, 236
- Grading of Recommendations Assessment, Development, and Evaluation (GRADE), 103, 121
- Granich, Reuben, 29, 95, 97, 104
- Grant, P. M., 97
- Greece, malaria elimination in, 331
- Green Light Committee, 240, 270
- Gregson, Simon A. J., 137
- Grossman, M., 217
- Guinea, tuberculosis in, 287
- Guinea worm infections, 2, 19, 337
- H**
- HAIs. *See* health care-associated infections
- Haiti
HIV/AIDS in, 130
- syphilis in, 129, 130
- tuberculosis in
community-based care, 266
information management system, 274
- Hallett, Timothy B., 95–96, 137
- Hargreaves, James R., 137
- Harripersaud, Katherine, 67
- Harris, Kate L., 137
- HAT. *See* human African trypanosomiasis
- HCC (hepatocellular carcinoma), 45
- HDL (high-density lipoprotein) cholesterol, 55
- Health Action, 394
- health care-associated infections (HAIs), 434, 438, 441
- Health Metrics Network, 190
- Heimbeck, J., 256
- Heller, P. S., 235
- helminthiases, 416, 421
- Henley, C., 215
- Hensen, Bernadette, 137
- hepatitis, 14–16, 401–10. *See also specific strains below*
diabetes mellitus comorbidity, 54
HIV/AIDS comorbidities, 48
incidence rates, 401–2, 402*f*, 402*t*
interventions, 16, 17*t*, 402*t*, 404–5
access to, 405, 407
blood supply safety, 16, 405
costs and cost-effectiveness, 406–7, 406*t*
harm reduction programs, 405
health care injection safety, 16, 405, 407
sanitation, 16, 404
vaccination, 16, 49, 404–5, 404*f*, 406
mortality rates, 16, 402, 403*f*, 403*m*
transmission of, 403–4
- hepatitis A
incidence rates, 401
sanitation improvement interventions, 404
transmission of, 403
vaccine for, 401, 404, 406
- hepatitis B
blood supply safety and, 405
burden of, 207
healthcare injection safety and, 405
incidence rates, 401
persons who inject drugs (PWIDs) and, 405
prevention interventions, 209
transmission of, 403
treatment access for, 405
vaccine for, 209, 213, 222, 401, 404, 406
- hepatitis C
blood supply safety and, 405
cost-effectiveness of interventions, 407
direct acting antiviral (DAA) medicines for, 401
healthcare injection safety and, 405

- HIV/AIDS comorbidity, 198
- incidence rates, 401
- mortality rates, 402
- persons who inject drugs (PWIDs) and, 405, 407
- transmission of, 403–4
- treatment access for, 405
- hepatitis D
 - incidence rates, 401
 - mortality rates, 402
 - transmission of, 403
 - vaccine for, 401
- hepatitis E
 - incidence rates, 401
 - sanitation improvement interventions, 404
 - transmission of, 403
 - vaccine for, 401, 404–5
- hepatocellular carcinoma (HCC), 45, 48
- herpes simplex virus (HSV-1 and HSV-2)
 - burden of, 207
 - HIV/AIDS comorbidities and, 46
 - incidence rates, 7
 - male circumcision and, 210
- high-density lipoprotein (HDL) cholesterol, 55
- high-income countries
 - antibiotic use in, 438
 - diabetes mellitus incidence rates in, 54
 - hepatitis in
 - cost-effectiveness of interventions, 407
 - treatment access, 405
 - HIV/AIDS in, 138
 - cancer comorbidity, 46
 - noncommunicable chronic comorbidities, 52
 - treatment interventions, 29
 - mortality rates in, 2, 2t
 - sexually transmitted infections in, 208
 - structural interventions, 217
- Histoplasma capsulatum*, 367
- HIV/AIDS, 5–9, 29–232
 - 90-90-90 targets, 30, 34–35, 39–40
 - adherence to treatment, 79–81
 - barriers, 79–80
 - cost-effectiveness, 81
 - decentralized care and, 81
 - guidelines, 79
 - improvement approaches, 80–81
 - measurement of, 79
 - peer counseling and, 81
 - rationale and coverage, 79
 - adolescents, 8
 - biology of transmission, 92–93
 - cancer comorbidity, 46–50
 - anal cancer, 48
 - behavioral interventions, 49
 - cervical cancer, 47
 - chemoprevention of, 49
 - epidemiology of, 46–47
 - hepatocellular carcinoma (HCC), 48
 - Kaposi sarcoma (KS), 47
 - lung cancer, 48
 - lymphoma, 47–48
 - pathogenesis of HIV-associated malignancies, 47
 - prevention strategies, 48–49
 - screening for, 49
 - vaccines and, 48–49
 - cardiovascular disease comorbidity, 52–54
 - ART impact on, 53
 - burden of, 52–53
 - epidemiology of, 52–53
 - factors associated with, 53
 - care continuum, 67–90, 68f
 - adherence, 79–81
 - linking to and engagement with care and treatment services, 75–77
 - retention in care, 77–79
 - testing services, 67–75, 71–74t
 - comorbidities, 45–66
 - bacterial vaginosis, 52
 - cancer, 46–50
 - cardiovascular disease, 52–54
 - diabetes mellitus, 54–55
 - dyslipidemia, 55–57, 55t
 - febrile illness, 368, 368t, 372
 - female reproductive health, 50–51
 - hepatitis C, 198
 - herpes simplex virus, 51
 - human papillomavirus (HPV), 51
 - malaria, 348
 - noncommunicable chronic comorbidities (NCCs), 52–57
 - other sexually transmitted infections, 51–52, 115
 - pelvic inflammatory disease, 51–52
 - sexually transmitted intestinal and enteric infections, 52
 - tuberculosis, 234, 239, 245
 - DALYs, 33–34
 - diabetes mellitus comorbidity, 54–55
 - burden of, 54
 - epidemiology of, 54
 - factors associated with, 54–55
 - dyslipidemia comorbidity, 55–57, 55t
 - burden of, 55
 - epidemiology of, 55
 - factors associated with, 55–56
 - febrile illness comorbidity, 368, 368t, 372
 - female reproductive health comorbidity, 50–51
 - family planning and, 50

- infertility and, 50–51
- intervention packages, 5, 5–6*t*
- key populations, 36–37
 - 90-90-90 targets among, 37
 - defining, 36–37
 - injecting drug users, 8, 36, 68, 160, 160*f*
 - men who have sex with men (MSM), 8, 36, 45, 68, 160, 160*f*
 - sex workers, 8, 36, 68, 159–60, 159*f*
 - surveillance, 39
- linking to and engagement with care and treatment services, 75–77
 - barriers, 75–76
 - cost-effectiveness, 76–77
 - guidelines, 75
 - measurement of, 75
 - rationale and coverage, 75
 - uptake improvement approaches, 76
- local epidemics, 157–78
 - allocative efficiency for interventions, 170–73, 171–73*f*, 172*t*
 - concentrated epidemics, 158, 159–60, 159–60*f*
 - cost-effectiveness of interventions, 170–73, 171–73*f*, 172*t*
 - generalized epidemics, 158, 160–61
 - geographic targeting and hotspot mapping, 167–70, 168–70*m*, 169*f*
 - injecting drug users, 8, 160
 - men who have sex with men (MSM), 8, 160, 160*f*
 - mixed epidemics, 158, 161
 - program science approach, 165–67
 - sex workers, 8, 159–60, 159*f*
 - tailoring responses to, 161–70, 161–62*f*, 164–65*f*, 166*m*, 167*f*, 168–70*m*
 - transmission dynamics and, 157–61, 158*m*
- malaria comorbidity, 348
- microepidemics, 35–36, 35–36*f*
 - surveillance, 39
- morbidity rates, 32–33, 32–33*f*
- mortality rates, 31–32, 31*f*
- mother-to-child transmission (MTCT), 7, 113–36
 - adherence to treatment and, 122
 - ART and, 121, 122
 - assessment of interventions, 124–25
 - burden of, 114–19, 114*t*, 116–19*m*
 - case studies, 129–30, 130*t*
 - community engagement and, 124
 - consequences of, 117–18
 - cost-effectiveness of prevention, 125–29, 126–27*t*, 126*f*
 - cross-cutting issues for, 123, 123*t*
 - effectiveness of interventions, 119–21, 120*t*
 - family planning and, 124
 - implementation of interventions, 121–24
 - male partner involvement and, 123–24
 - noncommunicable chronic comorbidities (NCCs), 52–57
 - cardiovascular disease, 52–54
 - diabetes mellitus, 54–55
 - dyslipidemia, 55–57, 55*t*
 - prevention interventions
 - barrier methods, 144
 - categorizing, 138–39
 - cost-effectiveness of, 137–56
 - costs of, 146–50, 148*t*, 149–50*f*
 - defining, 138–39
 - history of, 137–38
 - intervention endpoints, 139
 - male circumcision, 7, 8, 144–45
 - preexposure prophylaxis (PrEP), 7, 8, 145, 145*f*
 - prevention cascades, 140, 140*f*, 146, 147*f*
 - systematic reviews of, 140–43, 141*f*, 142–43*t*
 - targeting, 150–51, 151*f*
 - vaccines, 146
 - vaginal or rectal microbicides, 145–46
 - provider-initiated testing and counseling (PITC), 68
 - resource allocation modeling, 179–202
 - AIDS Epidemic Model (AEM), 180, 181–85*t*, 186, 192, 196–97
 - AIDS Impact Model (AIM), 186, 187
 - Avenir Health models, 180, 181–85*t*, 186–90
 - behavioral economics and, 198–99
 - comparison of models, 180–93, 181–85*t*, 198
 - controversies in, 199–200
 - Decision Makers' Program Planning Tool (DMPPT) model, 189–90, 196
 - Epidemiological Modeling (EMOD), 180, 181–85*t*, 186, 192
 - external validity of, 198
 - field experience with, 194–97
 - Global Health Decisions (GHD) model, 180, 181–85*t*, 186, 192–93
 - Global Resource Needs Estimate (GRNE) model, 187, 196
 - Goals model, 180, 181–85*t*, 188–89, 189*f*
 - implementation of, 198
 - OneHealth Tool, 180, 181–85*t*, 186, 190, 191*f*
 - Optima HIV model, 180, 181–85*t*, 190–92, 197
 - policy implications, 194–97
 - Resource Needs Model (RNM), 180, 181–85*t*, 187–88, 188*f*
 - role of, 180, 197
 - unit cost resources and, 198
 - What Works Reviews (WWR), 193–94, 193*f*, 195*f*
 - retention in care, 77–79
 - barriers, 77–78

- cost-effectiveness, 78–79
 - guidelines, 77
 - improvement approaches, 78
 - incentives for, 78–79
 - measurement of, 77
 - patient costs and, 78–79
 - rationale and coverage, 77
 - treatment supporters, use of, 78
 - sociocultural barriers to interventions, 7
 - surveillance
 - 90-90-90 targets, 39–40
 - challenges in, 37–40
 - expansion of, 30
 - key populations, 39
 - loss to follow-up, 38–39
 - microepidemics, 39
 - prevalence and incidence rates, 37–38
 - syphilis comorbidity, 115
 - testing services, 67–75, 71–74*t*
 - barriers, 69
 - community-based testing, 70, 75
 - cost-effectiveness, 70–75, 71–74*t*
 - early infant diagnosis, 75
 - guidelines, 68
 - measurement of, 68–69
 - rationale and coverage, 67–68
 - uptake improvement approaches, 69–70
 - voluntary counseling and testing, 70
 - treatment as prevention (TasP), 8, 91–112
 - biological studies, 103–4
 - clinical studies, 104
 - cost-effectiveness, 96–102, 98–99*t*
 - ecological studies, 94
 - effectiveness of, 93–96, 96*f*
 - measurement challenges, 94–95
 - modeling cost-effectiveness, 100–101
 - modeling population-level effectiveness, 95–96
 - pharmacological studies, 103–4
 - policy implications, 101–3
 - population-based studies, 94, 104, 104*b*
 - public health studies, 104
 - serodiscordant couples, 93, 102*b*
 - targeting of, 164
 - tuberculosis comorbidity, 234, 239, 245
 - HIV Infant Tracking System (Kenya), 76
 - HIV Modelling Consortium, 188
 - HIV Prevention Trials Network (HPTN), 91
 - Hodgkin lymphoma, 47, 48
 - Holmes, King K., 1, 210
 - Honduras, syphilis in, 203
 - Hong Kong SAR, China
 - malaria incidence rates in, 318
 - tuberculosis in
 - diagnosis, 249
 - incidence rates, 240
 - Horton, Susan, 1
 - hospitals
 - antibiotics usage in, 438, 438*f*, 441
 - febrile illness treatment in, 371–72
 - Hotez, P. J., 420
 - hotspot mapping, 167–70, 168–70*m*, 169*f*
 - HPTN (HIV Prevention Trials Network), 91
 - HPV. *See* human papillomavirus
 - Hsiao, W. C., 235
 - Humair, S., 97
 - human African trypanosomiasis (HAT)
 - cost-effectiveness of interventions, 422
 - incidence rates, 19, 415
 - mortality rates, 416
 - treatment interventions, 18, 423
 - human herpes virus (HHV-8), 47
 - human papillomavirus (HPV)
 - burden of, 7, 207
 - cervical cancer caused by, 47, 205
 - HIV/AIDS comorbidities and, 46
 - male circumcision and, 210
 - prevention interventions, 209
 - vaccinations for, 48–49, 209, 213, 222
 - hygiene, antibiotics usage and, 439–40
 - hypertension, 54
- I**
- IDUs (injecting drug users). *See* persons who inject drugs (PWIDs)
 - IGRAs (Interferon-Gamma Release Assays), 255
 - immune reconstitution inflammatory syndrome (IRIS), 251
 - immunizations. *See* vaccines and vaccinations
 - incidence rates
 - dengue, 365, 367, 368
 - febrile illness, 366–68, 368–69*t*
 - gonorrhoea, 203
 - hepatitis, 401–2, 402*f*, 402*t*
 - hepatitis D, 401
 - hepatitis E, 401
 - herpes simplex virus (HSV-1 and HSV-2), 7
 - human African trypanosomiasis (HAT), 19, 415
 - malaria, 315
 - syphilis, 203
 - trichomoniasis, 203
 - tuberculosis, 236–37, 237*f*
 - visceral leishmaniasis, 19, 415
 - India
 - antibiotic resistance in, 433, 434*f*, 435, 436*b*
 - antibiotic use in, 438, 442
 - febrile illness in, 367

- HIV/AIDS in
 - cancer comorbidity, 46
 - geographic targeting of interventions, 167
 - incidence rates, 35
 - linkage to care and treatment, 76, 77
 - localized intervention programs, 163
 - prevention interventions, 147, 148
 - testing services, 70, 75
 - treatment as prevention (TasP), 95, 97
- leprosy in, 415
- malaria control and elimination in, 320*b*, 348
 - cost-effectiveness of interventions, 331, 334
- sexually transmitted infections in, 216
- tuberculosis in
 - community-based care, 266, 268
 - diagnosis, 250
 - financing of interventions, 289–90, 290*t*
 - hospital-based care in, 264
 - incidence rates, 240
 - information management system, 275
 - pharmaceutical supply chain, 272
 - risk factors, 247
 - treatment interventions, 255, 282
 - vaccinations, 255, 256
- typhoid burden in, 373
- vector control interventions in, 419
- visceral leishmaniasis in, 19, 415, 419, 422
- Indonesia
 - febrile illness in, 367
 - HIV/AIDS in
 - mixed epidemics, 161, 162*f*
 - testing services, 70
 - malaria control in, 348
 - resource allocation modeling in, 197
 - syphilis in, 204
 - tuberculosis in, 274
 - typhoid burden in, 373
- indoor residual spraying (IRS), 349, 351
- influenza, 367, 368, 375, 440
- injecting drug users (IDUs). *See* persons who inject drugs (PWIDs)
- Innovative Vector Control Consortium, 321*b*, 358
- insecticide-treated nets (ITNs), 349, 352
- Institute for Disease Modeling, 180, 192
- Institute for Health Metrics and Evaluation, 31, 32–33, 237
- integrase inhibitors, 56
- Interferon-Gamma Release Assays (IGRAs), 255
- International AIDS Society, 38
- International Association of Physicians in AIDS Care, 75, 79
- International Epidemiological Databases to Evaluate AIDS, 38
- International Health Partnership and Joint Assessment of National Health Strategies and Plans, 190
- International Medicines Price Workbook* (Health Action), 394
- interventions. *See* treatment interventions; *specific interventions*
- intracytoplasmic sperm injection, 51
- intrauterine insemination, 51
- Investment Framework, 196
- in vitro fertilization, 51
- Iran, Islamic Republic of, HIV/AIDS in, 160, 161*f*
- Iraq, malaria elimination in, 315
- IRIS (immune reconstitution inflammatory syndrome), 251
- IRS (indoor residual spraying), 349, 351
- isoniazid, 234, 251
- ivermectin, 421
- J**
- Jamison, D. T., 290
- Japan
 - tuberculosis comorbidities in, 245
 - tuberculosis incidence rates in, 240
 - tuberculosis intervention program financing in, 280
- Japanese encephalitis virus (JEV), 367
- Jha, Prabhat, 1
- John-Stewart, Grace, 113
- Jordan, malaria elimination in, 332
- K**
- Kaestner, R., 217
- Kahn, James G., 179
- kanamycin, 252, 253
- Kaposi sarcoma (KS), 45, 46, 47
- Karim, Q. A., 214
- Kenya
 - HIV/AIDS in
 - concentrated epidemics, 160
 - geographic targeting of interventions, 168
 - key populations, 36
 - linkage to care and treatment, 76
 - persons who inject drugs (PWIDs), 160
 - prevention interventions, 148, 149
 - regional microepidemics, 35–36, 36*m*
 - retention in care, 78
 - testing services, 69, 70
 - treatment as prevention (TasP), 95, 104*b*
 - voluntary male medical circumcision and, 164
 - malaria vaccine program in, 12
 - pelvic inflammatory disease in, 52
 - sexually transmitted infections in, 215, 216
 - syphilis screening in, 123
 - tuberculosis in

- diagnosis, 262
 - hospital-based care in, 264
 - information management system, 275
 - key populations for HIV/AIDS, 36–37
 - 90-90-90 targets for, 37
 - defining, 36–37
 - injecting drug users, 8, 36, 68, 160, 160f
 - men who have sex with men (MSM), 8, 36, 45, 68, 160, 160f
 - sex workers, 8, 36, 68, 159–60, 159f
 - surveillance, 39
 - Khan, M. J., 333
 - kidney disease, 247
 - Kinuthia, John, 113
 - Kirby Institute, 170
 - Klebsiella pneumoniae*, 436b, 440
 - Knight, Gwen, 233, 287
 - Korea, Republic of, tuberculosis incidence rates in, 240
 - Kretzschmar, M. E., 96
 - Krishnaratne, Shari, 137, 140, 141
 - Kruk, M. E., 289
 - Kyrgyz Republic
 - HIV/AIDS in, 34
 - malaria elimination in, 315, 318
- L**
- Labrique, A. B., 273
 - Lancet* Commission on Investing in Health, 198, 427, 428
 - Lao People's Democratic Republic
 - febrile illness in, 367, 375, 376f
 - malaria elimination in, 321b
 - sexually transmitted infections in, 215
 - Larson, B. A., 129
 - La Ruche, G., 214
 - Latin America and Caribbean. *See also specific countries*
 - antibiotic use in, 443
 - behavioral change interventions in, 22
 - Chagas disease in, 419
 - HIV/AIDS in
 - comorbidities, 47
 - concentrated epidemics, 159, 160
 - key populations, 36
 - men who have sex with men (MSM), 160
 - malaria incidence rates in, 318
 - sexually transmitted infections in, 214
 - Latvia, tuberculosis in
 - community-based care, 266
 - diagnosis, 249
 - Laxminarayan, Ramanan, 290, 433
 - LDL (low-density lipoprotein) cholesterol, 55
 - Lebanon, malaria elimination in, 332
 - Leichliter, J. S., 223
 - leishmaniasis. *See* cutaneous leishmaniasis; visceral leishmaniasis
 - Lengeler, Christian, 347
 - Lenk, Edeltraud, 411
 - leprosy
 - cost-effectiveness of interventions, 422
 - incidence rates, 415
 - treatment interventions, 18, 423
 - tuberculosis and, 242, 246
 - leptospirosis, 366, 367, 368, 369, 375
 - lesbian, gay, bisexual, and transgender (LGBT) persons, 7, 36, 37. *See also* men who have sex with men (MSM)
 - Lesotho, HIV/AIDS in
 - behavioral change interventions, 164, 165, 165f
 - generalized epidemics, 161
 - Levi, J., 34
 - Levin, Carol, 113, 220, 347
 - Liberia, tuberculosis vaccinations in, 287
 - LICs. *See* low-income countries
 - linezolid, 253
 - liposomal amphotericin B (AmBisome), 422
 - Liu, Jenny, 315
 - Lives Saved Tool, 186–87
 - LLINs. *See* long-lasting insecticide-treated nets
 - local HIV/AIDS epidemics, 157–78
 - allocative efficiency for interventions, 170–73, 171–73f, 172t
 - concentrated epidemics, 158, 159–60, 159–60f
 - cost-effectiveness of interventions, 170–73, 171–73f, 172t
 - generalized epidemics, 158, 160–61
 - geographic targeting and hotspot mapping, 167–70, 168–70m, 169f
 - injecting drug users, 8, 160
 - men who have sex with men (MSM), 8, 160, 160f
 - mixed epidemics, 158, 161
 - program science approach, 165–67
 - sex workers, 8, 159–60, 159f
 - tailoring responses to, 161–70, 161–62f, 164–65f, 166m, 167f, 168–70m
 - transmission dynamics and, 157–61, 158m
 - Long, E. F., 97
 - long-lasting insecticide-treated nets (LLINs), 318, 325, 349, 352, 358–59
 - Lorougnon, F., 214
 - low-density lipoprotein (LDL) cholesterol, 55
 - Lubell, Yoel, 365, 375
 - Luecke, E., 141
 - lung cancer, 45, 48
 - Lyamuya, R. E., 39
 - lymphatic filariasis, 2, 415, 418, 423
 - lymphoma, 47–48

M

- Mabey, David, 113, 210
- Madagascar, malaria incidence rates in, 316
- Maddali, M. V., 95, 97
- Magadi, M. A., 35
- Makomva, Kudzai, 315
- malaria, 11, 14, 315–64
 - burden of, 348, 373, 413, 413*t*
 - comorbidities, 348
 - control interventions, 13*t*, 347–64
 - costs and cost-effectiveness of, 350–51
 - diagnosis, 350
 - effectiveness of, 349–50
 - environmental determinants, 351–52
 - health system factors, 352–53
 - medicine therapies, 353–56, 354–55*f*
 - social determinants, 351–52
 - surveillance, 350
 - systemic approaches, 351–53
 - treatments, 13*t*, 350
 - vector control, 349, 358–59, 358*f*
 - elimination and eradication, 315–46
 - artemisinin resistance and, 322–24, 323*m*
 - challenges to, 320–21*b*, 322–24
 - defined, 316–17, 317*b*
 - diagnosis and treatment, 327–29
 - epidemiological surveillance, 328–29
 - financing of, 330–36, 331*t*, 333–35*f*, 335–36*b*
 - high-risk populations, 322
 - interventions, 324–30, 324–25*t*
 - mass drug administration, 327–28
 - milestones and targets, 316, 316*t*
 - program management, 329–30
 - progress toward, 318–20, 319*m*, 320*t*
 - prospects for, 336–37
 - research priorities, 337*b*
 - vector control, 325–27
 - febrile illness comorbidity, 365
 - HIV/AIDS comorbidity, 348
 - incidence rates, 315
 - medicine therapies, 353–56, 354–55*f*
 - long-term chemoprotection, 355–56
 - transmission-blocking medicines, 355
 - mortality rates, 316
 - surveillance, 11
 - vaccines, 11, 329, 356–58, 357*f*
- Malaria Program Efficiency Analysis Tool (MPEAT), 336*b*
- Malaria Vaccine Funders Group, 356
- Malaria Vaccine Initiative, 356
- Malaria Vaccine Roadmap, 357
- Malawi
 - HIV/AIDS in
 - adherence to treatment, 79
 - ART interventions, 122
 - behavioral change interventions, 164, 165, 165*f*
 - intervention incentives, 143
 - linkage to care and treatment, 75, 76
 - mother-to-child transmission, 122
 - surveillance, 38
 - testing services, 68, 69, 70
 - malaria vaccine program in, 12
 - sexually transmitted infections in
 - partner notification, 215
 - structural interventions, 217
 - treatment interventions, 214
- Malaysia, malaria control in, 352
- Maldives, malaria incidence rates in, 318
- male circumcision. *See* voluntary male medical circumcision (VMMC)
- Mali, malaria elimination in, 334
- Manhart, L. E., 210
- Markov model, 390, 390*f*, 394
- Markowitz, S., 217
- Marrazzo, J. M., 144
- Marseille, Elliot, 179, 221
- Massad, L. S., 51
- mass drug administration (MDA), 327–28
- Mauritius
 - malaria elimination in, 321*b*, 331, 332
 - malaria incidence rates in, 318
- Mavedzenge, S. N., 141
- Mayaud, Philippe, 203, 210, 220
- Mayxay, M., 367
- McCarthy, F. D., 333
- McNairy, Margaret, 67
- MDA (mass drug administration), 327–28
- MDGs. *See* Millennium Development Goals
- measles, 2, 22
- Médecins Sans Frontières, 102, 274
- Medication Event Monitoring System, 79
- MEDLINE, 210
- melioidosis, 373
- MEMA kwa Vijana (intervention program), 216
- Ménard, Didier, 315
- Menon, Manoj, 45
- men who have sex with men (MSM)
 - HIV/AIDS among, 138
 - adherence to treatment, 80
 - concentrated epidemics, 160
 - incidence rates, 92
 - local epidemics, 8, 160, 160*f*
 - treatment as prevention (TasP), 93, 95
 - localized intervention programs for, 163, 167
 - preexposure prophylaxis (PrEP) for, 163

- resource allocation modeling and, 194
 - syphilis among, 203–4, 208
 - voluntary male circumcision and, 145
 - MERS (Middle East respiratory syndrome), 2
 - Mexico
 - HIV/AIDS in, 148
 - malaria elimination in, 332
 - Meyer-Rath, G., 100
 - microbicides
 - resource allocation modeling and, 194
 - sexually transmitted infections and, 210
 - microepidemics, 35–36, 35–36*f*, 39
 - Middle East and North Africa. *See also specific countries*
 - brucellosis in, 367
 - HIV/AIDS in
 - comorbidities, 47
 - concentrated epidemics, 159
 - key populations, 36
 - Millennium Development Goals (MDGs), 16, 123, 234, 241, 315, 348, 412
 - Miller, W. C., 96
 - Miller-Petrie, Molly, 433
 - mixed HIV/AIDS epidemics, 158, 161
 - modeling for resource allocation. *See* resource allocation modeling
 - Moldova, tuberculosis in
 - community-based care, 266
 - diagnosis, 264
 - Money, Deborah, 45
 - morbidity rates. *See also* comorbidities
 - dengue, 413, 413*t*
 - febrile illness, 397, 397*t*
 - HIV/AIDS, 32–33, 32–33*f*
 - neglected tropical diseases (NTDs), 413, 413*t*
 - sexually transmitted infections, 205
 - Morocco, malaria elimination in, 315
 - mortality rates
 - antiretroviral treatment (ART) and, 208
 - by country income group, 2, 2*t*
 - hepatitis, 16, 402, 403*f*, 403*m*
 - HIV/AIDS, 31–32, 31*f*
 - human African trypanosomiasis (HAT), 416
 - malaria, 316
 - neglected tropical diseases (NTDs), 412–13, 413*t*
 - schistosomiasis, 416
 - sexually transmitted infections, 205
 - tuberculosis, 234, 244
 - visceral leishmaniasis, 416
 - mother-to-child transmission (MTCT)
 - hepatitis, 404
 - HIV/AIDS, 7, 113–36
 - adherence to treatment and, 122
 - ART and, 121, 122
 - assessment of interventions, 124–25
 - burden of, 114–19, 114*t*, 116–19*m*
 - case studies, 129–30, 130*t*
 - community engagement and, 124
 - consequences of, 117–18
 - cost-effectiveness of prevention, 125–29, 126–27*t*, 126*f*
 - cross-cutting issues for, 123, 123*t*
 - effectiveness of interventions, 119–21, 120*t*
 - family planning and, 124
 - implementation of interventions, 121–24
 - male partner involvement and, 123–24
 - resource allocation modeling and, 195
 - Mozambique
 - HIV/AIDS in
 - prevention interventions, 149
 - retention in care, 78
 - treatment as prevention (TasP), 102
 - malaria elimination in, 321*b*
 - sexually transmitted infections in, 221
 - tuberculosis in, 264
 - MRSA, 433, 434–35
 - MSM. *See* men who have sex with men
 - MTCT. *See* mother-to-child transmission
 - mumps, 2
 - Murdoch, D. R., 367
 - murine typhus, 367
 - Murray, Megan, 233
 - Myanmar
 - malaria elimination in, 321*b*, 323
 - resource allocation modeling in, 197
 - tuberculosis in, 264
 - mycetoma, 412
 - Mycobacterium avium*, 367
 - Mycobacterium bovis*, 242, 255
 - Mycobacterium kansasii*, 256
 - Mycobacterium leprae*, 242
 - Mycobacterium microti*, 256
 - Mycobacterium tuberculosis*, 233, 242, 244–45, 367, 433
 - Mycobacterium ulcerans*, 414
 - Mycoplasma genitalium*, 210
 - myocardial infarction, 52, 53
- N**
- NAATs (nucleic acid amplification tests), 249
 - NADCs (non-AIDS defining cancers), 45, 46
 - Namibia, malaria elimination in, 321*b*
 - Naranbhai, V., 248
 - Nardell, Edward, 233
 - Natunen, K., 220, 222
 - NCCs. *See* noncommunicable chronic comorbidities
 - Ndowa, F., 220
 - needle and syringe programs (NSPs), 161, 163, 407

- neglected tropical diseases (NTDs), 16–19, 411–48.
See also specific diseases
 burden of, 19, 412–15, 413–14*t*, 414*f*
 defined, 24*n*6
 global targets for control, elimination, and eradication, 412, 412*t*
 proof of concept for, 415–16, 415*f*, 416*m*
 intervention packages, 16–18, 18*t*, 416–20, 417–19*t*, 417*f*
 cost and cost-effectiveness of, 420–22, 420*t*
 fairness of, 422
 individual treatment and care, 419–20
 large-scale prevention to entire communities, 18, 416–18
 preventive chemotherapy, 18, 416–18, 420, 420*t*
 return on investment for, 425–27, 426*t*
 targeting of, 423–25, 423–24*f*
 morbidity rates, 413, 413*t*
 mortality rates, 412–13, 413*t*
 preventive chemotherapy, 412, 417, 417*f*, 417*t*
 vector control, 412, 418–19, 418*t*, 421
- Neisseria* spp., 366, 433, 435
- Nepal
 antibiotic use in, 438
 antimicrobial resistance in, 439
 febrile illness in, 367
 malaria elimination in, 332
 vector control interventions in, 419
 visceral leishmaniasis in, 19, 415
- Newby, Gretchen, 315
- Newton, Paul N., 365
- Next Generation Indoor Residual Spray Project, 321*b*
- NHL (non-Hodgkin lymphoma), 45, 46, 48
- nifurtimox-eflornithine combination therapy (NECT), 422
- Nigeria
 antibiotic resistance in, 433, 434*f*
 ascariasis in, 413
 HIV/AIDS in
 cancer comorbidity, 46
 dyslipidemia comorbidity, 56
 geographic targeting of interventions, 167–68, 168–69*m*, 169*f*
 program science approach, 166–67, 167*f*
 malaria in, 348
 cost-effectiveness of interventions, 334
 mortality rates, 316
- NNRTIs (non-nucleoside reverse transcriptase inhibitors), 55
- non-AIDS defining cancers (NADCs), 45, 46
- noncommunicable chronic comorbidities (NCCs), 52–57
 cardiovascular disease, 52–54
 diabetes mellitus, 54–55
 dyslipidemia, 55–57, 55*t*
- non-Hodgkin lymphoma (NHL), 45, 46, 48
- nonmalarial fever. *See* febrile illness
- non-nucleoside reverse transcriptase inhibitors (NNRTIs), 55
- NRTIs (nucleoside reverse transcriptase inhibitors), 47, 56
- NSPs (needle and syringe programs), 161, 163, 407
- NTDs. *See* neglected tropical diseases
- nucleic acid amplification tests (NAATs), 249
- nucleoside reverse transcriptase inhibitors (NRTIs), 47, 56
- Nundy, S., 289
- Nwankwo, Uzoma, 411
- O**
- Obiero, J., 145
- Odeny, T. A., 39
- Oman, malaria elimination in, 315, 327
- onchocerciasis, 418, 423
- OneHealth Tool, 180, 181–85*t*, 186, 190, 191*f*
- OpenMRS platform, 274
- opioid substitution therapy (OST), 161, 163
- Optima HIV model, 157, 170, 180, 181–85*t*, 190–92, 197
- oral sex, 207
- Orientia tsutsugamushi*, 367, 373
- Over, M., 100
- Owens, D. K., 97
- Owens, J. P., 283
- Owusu-Edusei, K., Jr., 223
- P**
- Padian, Nancy, 29, 146
- Pakistan
 antibiotic resistance in, 433, 434*f*
 hepatitis in
 incidence rates, 16
 prevalence, 402
 HIV/AIDS in
 concentrated epidemics, 160
 geographic targeting of interventions, 167, 170*m*
 key populations, 36
 persons who inject drugs (PWIDs), 160
 malaria control and elimination in, 333, 334, 348
 sexually transmitted infections in, 217
 tuberculosis in
 community-based care, 268
 hospital-based care in, 264
 information management system, 273, 274
- palliative care, 254

- PaMZ (pretomanid/moxifloxacin/pyrazinamide), 277, 284
- Pant, Suraj, 433
- Paraguay, malaria elimination in, 315, 318
- Partners in Health, 273, 274
- PARTNER Study, 93
- Peeling, Rosanna W., 113, 130
- peer counseling, 81
- pelvic inflammatory disease, 46, 51–52
- penicillin, 208, 420
- Penno, E. C., 375
- persons who inject drugs (PWIDs)
 - antiretroviral treatment (ART) for, 163
 - hepatitis and, 405
 - HIV/AIDS among, 138
 - concentrated epidemics, 160
 - interventions targeting, 162–63
 - local epidemics, 8, 160
 - treatment as prevention (TasP), 95
 - preexposure prophylaxis (PrEP) for, 163
- Peru
 - HIV/AIDS in
 - concentrated epidemics, 160, 160*f*
 - men who have sex with men (MSM), 160
 - mother-to-child transmission, 130
 - sexually transmitted infections in, 216
 - syphilis in, 129, 130
 - tuberculosis in
 - community-based care, 264
 - diagnosis, 262
 - information management system, 273, 274, 275
- Peterman, T. A., 208
- Pettifor, A., 214
- phenytoin, 253
- Philippines
 - leptospirosis in, 373
 - malaria elimination in, 331, 334
 - resource allocation modeling in, 197
 - tuberculosis in, 275
- Phillips, Allison, 315
- PITC (provider-initiated testing and counseling), 68
- Plasmodium falciparum*, 347–48, 367
- Plasmodium knowlesi*, 348
- Plasmodium malariae*, 348
- Plasmodium ovale*, 348
- Plasmodium vivax*, 347–48, 367, 386
- pneumonia, 19, 366, 378, 433
- point-of-care tests (POCTs)
 - cost-effectiveness analysis, 378
 - for febrile illness, 369, 372, 374, 378
 - for influenza, 375
 - for malaria, 378
 - for sepsis, 375
- polio, 2, 22, 336–37
- Population Effects of ART to Reduce HIV Transmission (PopART), 104*b*
- Population HIV Impact Assessment (PHIA), 68
- Powers, K. A., 96
- preexposure prophylaxis (PrEP)
 - antiretroviral treatment (ART) and, 93
 - cost-effectiveness of, 137, 149
 - female reproductive health and, 50
 - HIV/AIDS, 7, 8, 145, 145*f*
 - localized intervention programs, 163
 - resource allocation modeling and, 194
 - sexually transmitted infection prevention via, 209
- pregnant women
 - febrile illness and, 368, 368*t*
 - hepatitis vaccinations for, 404
 - malaria among, 322, 348
 - maternal screening for sexually transmitted infections, 222
 - syphilis among, 208, 222
 - tuberculosis among, 253
- President's Emergency Plan for AIDS Relief (PEPFAR), 20, 102, 103, 138, 149, 196
- President's Malaria Initiative, 20, 349
- pretomanid/moxifloxacin/pyrazinamide (PaMZ), 277, 284
- prevention interventions
 - Chagas disease, 421
 - chemotherapy, 412, 417, 417*f*, 417*t*
 - dengue, 421
 - HIV/AIDS
 - barrier methods, 144, 210
 - categorizing, 138–39
 - cost-effectiveness of, 137–56
 - costs of, 146–50, 148*t*, 149–50*f*
 - defining, 138–39
 - history of, 137–38
 - intervention endpoints, 139
 - male circumcision, 7, 8, 144–45
 - preexposure prophylaxis (PrEP), 7, 8, 145, 145*f*
 - prevention cascades, 140, 140*f*, 146, 147*f*
 - systematic reviews of, 140–43, 141*f*, 142–43*t*
 - targeting, 150–51, 151*f*
 - vaccines, 146
 - vaginal or rectal microbicides, 145–46
 - sexually transmitted infections, 144, 210
 - treatment as prevention (TasP), 8, 91–112
 - biological studies, 103–4
 - clinical studies, 104
 - cost-effectiveness, 96–102, 98–99*t*
 - ecological studies, 94
 - effectiveness of, 93–96, 96*f*
 - measurement challenges, 94–95

- modeling cost-effectiveness, 100–101
 - modeling population-level effectiveness, 95–96
 - pharmacological studies, 103–4
 - policy implications, 101–3
 - population-based studies, 94, 104, 104*b*
 - public health studies, 104
 - serodiscordant couples, 93, 102*b*
 - targeting of, 164
 - tuberculosis, 255–61
 - in hospitals, 259
 - infection control in congregate settings, 258–61
 - preventive therapy, 257–58
 - transmission control, 258–61
 - vaccinations, 255–56
 - primaquine, 328, 350, 353
 - proctitis, 52
 - proctocolitis, 52
 - Promoting Maternal-Infant Survival Everywhere (PROMISE), 115, 131*n*7
 - prostitution. *See* sex workers
 - protease inhibitors, 56
 - Proteus mirabilis*, 366
 - provider-initiated testing and counseling (PITC), 68
 - Pseudomonas* spp., 366
 - PubMed, 193
 - Punjabi, N. H., 367
 - PWIDs. *See* persons who inject drugs
 - pyrazinamide, 251, 253
 - pyrethroids, 326, 359
- Q**
- Q fever, 366, 367, 368
 - Quinn, T. C., 92
 - quinolones, 208, 435
- R**
- rabies, 416
 - Radhakrishna, S., 256
 - rapid diagnostic tests (RDTs), 350, 385, 386
 - RBM. *See* Roll Back Malaria Partnership
 - receptivity risk maps, 336*b*
 - Reddy, E. A., 366
 - reproductive health
 - ART and, 50
 - family planning and, 50
 - HIV/AIDS comorbidities and, 45–46, 50–51
 - infertility and, 50–51
 - STIs and, 7
 - República Bolivariana de Venezuela, malaria in, 316
 - ResistanceMap, 443
 - resource allocation modeling, 179–202
 - AIDS Epidemic Model (AEM), 180, 181–85*t*, 186, 192, 196–97
 - AIDS Impact Model (AIM), 186, 187
 - antiretroviral treatment (ART) and, 197, 198
 - Avenir Health models, 180, 181–85*t*, 186–90
 - behavioral economics and, 198–99
 - comparison of models, 180–93, 181–85*t*, 198
 - controversies in, 199–200
 - Decision Makers' Program Planning Tool (DMPPT) model, 189–90, 196
 - Epidemiological Modeling (EMOD), 180, 181–85*t*, 186, 192
 - external validity of, 198
 - field experience with, 194–97
 - Global Health Decisions (GHD) model, 180, 181–85*t*, 186, 192–93
 - Global Resource Needs Estimate (GRNE) model, 187, 196
 - Goals model, 180, 181–85*t*, 188–89, 189*f*
 - in health system framework, 235*f*, 236
 - implementation of, 198
 - OneHealth Tool, 180, 181–85*t*, 186, 190, 191*f*
 - Optima HIV model, 180, 181–85*t*, 190–92, 197
 - policy implications, 194–97
 - Resource Needs Model (RNM), 180, 181–85*t*, 187–88, 188*f*
 - role of, 180, 197
 - unit cost resources and, 198
 - What Works Reviews (WWR), 193–94, 193*f*, 195*f*
 - Resource Needs Model (RNM), 180, 181–85*t*, 187–88, 188*f*
 - Resources for the Awareness of Population Impacts on Development, 186
 - retention in care, 77–79
 - Réunion, malaria in, 318
 - Revill, Paul, 137
 - rickettsial infections, 367
 - rifampicin, 234, 251, 253, 272
 - Rift Valley fever, 367
 - RNM. *See* Resource Needs Model
 - Roberts, M., 235
 - Roll Back Malaria (RBM) Partnership, 316, 318, 348–49
 - Romania, tuberculosis in, 266
 - Ross, D. A., 141
 - Ross, Ronald, 347
 - rubella, 2
 - Rubin, Eric, 233
 - Russian Federation
 - antibiotic use in, 438
 - HIV/AIDS in
 - 90-90-90 targets and, 34
 - burden of, 116
 - prevention interventions, 148
 - tuberculosis in
 - diagnosis, 263*b*

- hospital-based care in, 264
 - incidence rates, 237
 - infection control, 259, 260*b*
 - Rutstein, S. E., 221
 - Rwanda
 - HIV/AIDS in
 - cardiovascular disease comorbidity, 53
 - mother-to-child transmission, 124
 - prevention interventions, 148
 - tuberculosis in
 - community-based care, 266
 - information management system, 275
- S**
- Sachs, J. D., 333
 - Sahin-Hodoglugil, N. N., 220
 - Salmonella enterica*, 366, 367, 372, 373, 434, 436*b*
 - Salomon, Joshua, 233, 283
 - Samb, B., 235
 - Samyshkin, Y., 235
 - sanitation
 - antibiotics usage and, 439–40
 - hepatitis treatment interventions, 16, 404
 - Santos, Michael, 137
 - São Tomé and Príncipe, malaria elimination in, 332
 - SARS (severe acute respiratory syndrome), 2
 - schistosomiasis, 416, 423
 - scrub typhus, 367, 368, 369
 - SDGs. *See* Sustainable Development Goals
 - SEARCH (Sustainable East Africa Research on Community Health), 104*b*
 - Sengupta, A., 289
 - sepsis, 375
 - service delivery in health system framework, 235*f*, 236
 - sexually transmitted infections (STIs), 5–9, 203–32.
 - See also specific infections*
 - adolescents, 8
 - AIDS mortality and, 208
 - burden of, 7–8, 204–7
 - clinician online education for, 9
 - clustering patterns, 208–9
 - diagnosis, 206
 - epidemiology of, 207–8
 - globalization and, 208–9
 - gonococcal antimicrobial resistance, 208
 - key populations, 208
 - in LMICs, 206–7
 - in lower middle income countries, 8
 - morbidity rates, 205
 - mortality rates, 205
 - mother-to-child transmission (MTCT), 208
 - pharmacy treatment of, 9
 - prevalence of, 203–4, 204*f*, 204*m*, 205*t*, 206*f*
 - prevention interventions, 8–9, 9–10*t*, 209–23
 - behavioral change interventions, 210, 219
 - case management, 214, 220
 - community interventions, 216–17, 221–22
 - cost-effectiveness of, 217–22, 218–19*t*
 - effectiveness of interventions, 210–17, 211–13*t*
 - HIV-related benefits of, 222
 - HPV vaccines, 210, 213, 220, 222
 - income inequality and, 222–23
 - male circumcision, 210, 219–20
 - mass treatment, 216, 221
 - maternal screening, 222
 - microbicides, 213–14, 220
 - partner notification and management, 214–15, 221
 - periodic presumptive treatment, 215–16, 221
 - research agenda, 223
 - structural interventions, 216–17, 221–22
 - targeted interventions, 215–16, 221
 - sexual behaviors and, 8, 207
 - social determinants, 208–9
 - sex workers
 - HIV/AIDS among, 138
 - adherence to treatment, 81
 - concentrated epidemics, 159, 159*f*
 - local epidemics, 8, 159–60, 159*f*
 - localized intervention programs, 163
 - treatment as prevention (TasP), 95
 - localized intervention programs for, 167
 - Sharma, N. P., 367
 - Shaw, A. V., 366
 - Shigella* spp., 366
 - Shretta, Rima, 315, 347
 - Sierra Leone, tuberculosis in, 287
 - silicosis, 247
 - Singapore
 - malaria in
 - cost-effectiveness of interventions, 332
 - incidence rates, 318
 - syphilis in, 203
 - tuberculosis in
 - diagnosis, 249
 - incidence rates, 240
 - Situational Analysis of Sexual Health, 209
 - smallpox, 336–37, 338*n5*
 - SMART (Strategies for Management of Antiretroviral Therapy), 53
 - snakebites, 16
 - sociocultural barriers to interventions, 7
 - soil-transmitted helminthiases (STH), 416, 421
 - Solomon Islands, malaria elimination in, 321*b*
 - South Africa
 - antibiotic use in, 438, 442

- antimicrobial resistance in, 439, 440, 440*b*
- bacterial vaginosis in, 52
- HIV/AIDS in
 - adherence to treatment, 80, 81
 - behavioral change interventions, 164
 - burden of, 115
 - cancer comorbidity, 46
 - cardiovascular disease comorbidity, 53
 - comorbidities, 46
 - dyslipidemia comorbidity, 55
 - generalized epidemics, 160, 161*f*
 - incidence rates, 35
 - linkage to care and treatment, 76, 77
 - mother-to-child transmission, 125, 129–30
 - prevention interventions, 148
 - retention in care, 78
 - testing services, 70
 - treatment as prevention (TasP), 94, 95, 96, 97, 101, 104*b*, 164
 - voluntary male medical circumcision and, 164
- malaria elimination in, 321*b*, 331
- sexually transmitted infections in
 - community-based interventions, 217
 - microbicide interventions, 214
 - targeting of interventions, 215
- tuberculosis in
 - community-based care, 266
 - comorbidities, 245
 - costs of treatment, 285, 287
 - diagnosis, 250, 262, 263
 - hospital-based care in, 264
 - incidence rates, 236
 - infection control, 259, 260, 261
 - preventive therapy, 257–58
 - research and development, 283
 - treatment interventions, 253, 282
 - vaccinations, 256
- voluntary male circumcision in, 144
- South Asia
 - antibiotic resistance in, 434
 - febrile illness in, 367–68
 - hepatitis in
 - incidence rates, 16
 - mortality rates, 401
 - HIV/AIDS in
 - comorbidities, 47
 - morbidity rates, 33
- South-East Asia
 - febrile illness in, 367–68
 - hepatitis in, 404
 - malaria control in, 348
 - sexually transmitted infections in, 203
 - tuberculosis in, 237
- Spectrum (modeling software), 186, 187, 200*n2*
- sperm washing, 51
- Sri Lanka
 - febrile illness in, 386
 - malaria in, 315, 317, 318, 330*b*, 338*n1*
 - cost-effectiveness of interventions, 331, 332
 - incidence rates, 318
 - vector control, 327
- Standards for Reporting of Diagnostic Accuracy, 372
- Staphylococcus aureus*, 367, 433, 436*b*, 440
- Steen, R., 215
- stigma
 - HIV/AIDS, 36, 37, 69, 79
 - leishmaniasis, 422
 - sexually transmitted infections in, 206
 - of visceral leishmaniasis, 415
- STIs. *See* sexually transmitted infections
- Stop TB Initiative, 240
- Stop TB Partnership, 240, 241, 291
- Stover, John, 179, 188
- Strategies for Management of Antiretroviral Therapy (SMART), 53
- Streptococcus pneumoniae*, 367, 372
- streptomycin, 253
- Sub-Saharan Africa. *See also specific countries*
 - antibiotic resistance in, 434
 - brucellosis in, 367
 - cervical cancer in, 47
 - febrile illness in, 373, 385
 - HIV/AIDS in, 5, 29, 30
 - 90-90-90 targets and, 34
 - adherence to treatment, 79, 80
 - ART and, 35
 - burden of, 115
 - comorbidities, 47
 - concentrated epidemics, 159, 160
 - cost-effectiveness of interventions, 67
 - diabetes mellitus comorbidity, 54
 - dyslipidemia comorbidity, 56
 - geographic targeting of interventions, 167–68
 - key populations, 36
 - linkage to care and treatment, 75, 76
 - local epidemics, 158, 158*m*
 - mortality rates, 31, 31*f*
 - mother-to-child transmission, 126, 130
 - noncommunicable chronic comorbidities, 57
 - persons who inject drugs (PWIDs), 160
 - prevention interventions, 148
 - regional microepidemics, 35
 - retention in care, 77, 78
 - surveillance, 38
 - testing services, 69, 70
 - treatment as prevention (TasP), 95, 97

- Kaposi sarcoma (KS) incidence in, 47
 - malaria control and elimination in, 11, 316, 321*b*, 348, 353
 - treatment interventions, 350
 - vector control, 325, 349
 - mother-to-child transmission, 129, 130
 - neglected tropical diseases in
 - burden of, 413
 - cost-effectiveness of interventions, 421
 - resource allocation modeling in, 195, 196
 - sexually transmitted infections in, 203
 - partner notification, 221
 - structural interventions, 217
 - treatment case management, 220
 - syphilis in, 122
 - tuberculosis in
 - burden of, 237
 - community-based care, 268
 - diagnosis, 262, 263
 - incidence rates, 237
 - treatment interventions, 282
 - voluntary male circumcision in, 51, 144
 - Sudan, visceral leishmaniasis in, 415
 - sulfadoxine/pyrimethamine (SP), 385
 - Supervie, V., 93
 - surveillance
 - antibiotics usage, 442–43
 - febrile illness, 375
 - HIV/AIDS
 - 90-90-90 targets, 39–40
 - challenges in, 37–40
 - expansion of, 30
 - key populations, 39
 - loss to follow-up, 38–39
 - microepidemics, 39
 - prevalence and incidence rates, 37–38
 - malaria, 11, 328–29, 350
 - Sustainable Development Goals (SDGs), 11, 24*n*4, 234, 241, 412, 425, 427
 - Sutherland, I., 256
 - Svandova, E., 256
 - Swanson, R. C., 235
 - Swaziland
 - HIV/AIDS in
 - allocative efficiency for interventions, 171–73, 172*f*, 172*t*
 - concentrated epidemics, 159
 - generalized epidemics, 161
 - treatment as prevention (TasP), 164
 - malaria elimination in, 321*b*
 - cost-effectiveness of interventions, 332
 - surveillance, 328–29
 - tuberculosis incidence rates in, 240
 - Sweat, M., 221
 - syphilis
 - burden of, 7, 207
 - HIV comorbidity, 115
 - incidence rates, 203
 - mother-to-child transmission (MTCT), 113, 208
 - burden of, 114–19, 114*t*, 116–19*m*
 - consequences of, 118–19
 - cost-effectiveness of prevention, 125–29, 126*f*, 128–29*t*
 - cross-cutting issues for, 123, 123*t*
 - effectiveness of interventions, 121
 - penicillin treatment and, 121
 - screening during pregnancy, 222
 - pediatric burden of, 116–17, 117*m*
 - transmission of, 114–15
 - Syrian Arab Republic, malaria elimination in, 315, 332
- T**
- Taaffe, Jessica, 157
 - tafenoquine, 327
 - Taiwan, China
 - HIV/AIDS in, 94
 - malaria elimination in, 318, 338*n*3
 - tuberculosis in, 255
 - Tajikistan, malaria elimination in, 321*b*
 - Tanner, Marcel, 347
 - Tanser, F., 94
 - Tanzania
 - febrile illness analytical model, 386–97, 391–97*t*.
See also febrile illness
 - HIV/AIDS in
 - behavioral change interventions, 164, 165, 165*f*
 - dyslipidemia comorbidity, 55, 56
 - testing services, 69, 70
 - malaria elimination in, 317
 - sexually transmitted infections in
 - community-based interventions, 216
 - treatment interventions, 214
 - syphilis in, 117, 121, 122, 129, 208
 - tuberculosis in
 - community-based care, 266
 - hospital-based care in, 264
 - research and development, 283
 - Tatarsky, Allison, 315
 - TB Alliance, 240, 278
 - TB Supranational Reference Laboratory Network, 249
 - Tediosi, Fabrizio, 347
 - telemedicine to support health workers, 274
 - Terris-Prestholt, F., 129, 220
 - testing services for HIV/AIDS, 67–75, 71–74*t*
 - barriers, 69
 - community-based testing, 70, 75

- cost-effectiveness, 70–75, 71–74*t*
- early infant diagnosis, 75
- guidelines, 68
- measurement of, 68–69
- rationale and coverage, 67–68
- uptake improvement approaches, 69–70
- voluntary counseling and testing, 70
- tetanus, 22
- tetracycline, 208
- Thailand
 - HIV/AIDS in
 - concentrated epidemics, 160
 - diabetes mellitus comorbidity, 54
 - dyslipidemia comorbidity, 55
 - geographic targeting of interventions, 168
 - men who have sex with men (MSM), 160
 - mother-to-child transmission, 127
 - sex workers and, 138
 - malaria elimination in, 321*b*, 332, 334
 - sexually transmitted infections in, 210
 - tuberculosis in, 264
- Thirumurthy, Harsha, 67
- ThoughtWorks, 274
- Total Community Treatment, 420
- trachoma, 418, 423
- Trajman, A., 283
- transgender persons. *See* lesbian, gay, bisexual, and transgender (LGBT) persons
- TREAT Asia HIV Observational Database, 46
- treatment as prevention (TasP), 8, 91–112
 - biological studies, 103–4
 - clinical studies, 104
 - cost-effectiveness, 96–102, 98–99*t*
 - ecological studies, 94
 - effectiveness of, 93–96, 96*f*
 - measurement challenges, 94–95
 - modeling cost-effectiveness, 100–101
 - modeling population-level effectiveness, 95–96
 - pharmacological studies, 103–4
 - policy implications, 101–3
 - population-based studies, 94, 104, 104*b*
 - public health studies, 104
 - serodiscordant couples, 93, 102*b*
 - targeting of, 164
- treatment interventions
 - behavioral, 23
 - cost-effectiveness of, 20–22, 21*f*
 - drug development and, 23
 - febrile illness, 14, 14–15*t*, 370–71*t*, 371–72
 - hepatitis, 16, 17*t*, 402*t*, 404–5
 - access to, 405, 407
 - blood supply safety, 16, 405
 - costs and cost-effectiveness, 406–7, 406*t*
 - harm reduction programs, 405
 - health care injection safety, 16, 405, 407
 - sanitation, 16, 404
 - vaccination, 16, 49, 404–5, 404*f*, 406
 - human African trypanosomiasis (HAT), 18, 423
 - leprosy, 18, 423
 - neglected tropical diseases (NTDs), 16–18, 18*t*, 416–20, 417–19*t*, 417*f*
 - cost and cost-effectiveness of, 420–22, 420*t*
 - fairness of, 422
 - individual treatment and care, 419–20
 - large-scale prevention to entire communities, 18, 416–18
 - preventive chemotherapy, 18, 416–18, 420, 420*t*
 - return on investment for, 425–27, 426*t*
 - targeting of, 423–25, 423–24*f*
 - vector transmission prevention, 418–19, 418*t*, 421
 - scale-up of, 22–23
 - services integration and, 23
 - sexually transmitted infections, 8–9, 9–10*t*, 209–23
 - behavioral change interventions, 210, 219
 - case management, 214, 220
 - community interventions, 216–17, 221–22
 - cost-effectiveness of, 217–22, 218–19*t*
 - effectiveness of interventions, 210–17, 211–13*t*
 - HIV-related benefits of, 222
 - HPV vaccines, 210, 213, 220, 222
 - income inequality and, 222–23
 - male circumcision, 210, 219–20
 - mass treatment, 216, 221
 - maternal screening, 222
 - microbicides, 213–14, 220
 - partner notification and management, 214–15, 221
 - periodic presumptive treatment, 215–16, 221
 - research agenda, 223
 - structural interventions, 216–17, 221–22
 - targeted interventions, 215–16, 221
 - targeting of, 22
 - tuberculosis, 234, 250–55, 252*t*
 - vaccine development and, 23
 - visceral leishmaniasis, 18, 423
- Treponema pallidum*, 216
- trichomoniasis, 7, 145, 203, 207, 210
- triglycerides, 55
- Trypanosoma cruzi*, 414
- tuberculosis, 10–11, 233–313
 - burden of, 237–42, 238–39*t*
 - community-based care, 264–69, 266*f*, 267*t*
 - efficiency and effectiveness, 265–66, 267*t*
 - human resource challenges, 267

- private sector challenges, 267–68
- recommendations, 292
- targeting, 268–69
- comorbidities, 234, 239, 245–46
- cost-effectiveness of interventions, 281–89, 285–86t, 288f
- diagnosis, 248–50, 249b, 261–64, 263b, 292
- DOTS strategy, 291
- financing for programs, 280–81, 280–81f, 289–90, 290t
- global response, 240, 240b, 241f, 242b
- historical trends, 236–37
- HIV/AIDS comorbidity, 234, 239, 245
- incidence rates, 236–37, 237f
- information management and, 272–75
- mortality rates, 234, 244
- prevention interventions, 255–61
 - in congregate settings, 258–61
 - in hospitals, 259
 - preventive therapy, 257–58
 - transmission control, 258–61
 - vaccinations, 255–56
- research and development, 275–80
 - medication optimization, 276–77
 - recommendations, 293
 - treatment interventions, 277–78
 - vaccines, 278–79
- risk factors, 246–48, 246–47t
- screening, 248–50, 249b
- SMS reminders to improve adherence, 274–75
- stages and intervention points, 242–44, 243f
- strains of, 244–45
- supply chains and, 269–72, 270–71f
- telemedicine to support health workers, 274
- transmission control, 258–61
 - air disinfection, 260
 - cost-effectiveness of, 260
 - in hospitals, 259
 - in households, 261
 - masks and respirators, 260–61
 - measuring effectiveness of, 259–60
 - principles of, 259
- treatment interventions, 12t, 234, 250–55, 252t
 - adherence, 274–75
 - antidiabetic treatment, 254
 - ART, 253–54
 - cascade of care, 254–55
 - DOTS strategy, 234, 240–41, 240b, 254, 291–92
 - drug toxicities and interactions, 253
 - first-line treatment of drug-susceptible TB, 251
 - palliative care, 254
 - recommendations, 292

- second-line treatment of MDR TB, 251–53
- surgery, 254
- vaccinations, 233, 243
- universal public financing for treatment of, 289–90, 290t

- Tuberculosis Impact Model and Estimates, 186
- Turkey, malaria elimination in, 315
- Turkmenistan, malaria elimination in, 315, 329b
- typhoid, 367, 368, 369, 373
- Typhoid Fever Surveillance in Africa Program, 434

U

Uganda

- HIV/AIDS in
 - adherence to treatment, 80, 81
 - cancer comorbidity, 46
 - diabetes mellitus comorbidity, 54
 - incidence rates, 138
 - linkage to care and treatment, 76
 - mother-to-child transmission, 130
 - prevention interventions, 148
 - retention in care, 78
 - surveillance, 38
 - testing services, 69, 70, 75
 - treatment as prevention (TasP), 95, 100, 104b
 - voluntary male medical circumcision and, 164
- malaria in
 - cost-effectiveness of interventions, 333
 - incidence rates, 316
- neglected tropical diseases in, 422
- sexually transmitted infections in
 - mass treatment interventions, 216
 - partner notification, 215
 - treatment interventions, 214
- syphilis in, 130
- tuberculosis in
 - hospital-based care in, 264
 - treatment interventions, 282
- voluntary male circumcision in, 144

Ukraine

- HIV/AIDS in, 160
- tuberculosis in, 264

Ukwaja, K. N., 285

- UNAIDS. *See* United Nations Programme on HIV/AIDS

- United Arab Emirates, malaria elimination in, 315

United Kingdom

- antimicrobial resistance in, 439, 443
- sexually transmitted infections in, 207
- tuberculosis in
 - financing intervention programs, 280

- incidence rates, 236
 - research and development, 279
 - vaccinations, 255
 - United Nations Office on Drugs and Crime, 163
 - United Nations Programme on HIV/AIDS (UNAIDS), 5, 30, 31, 32, 67, 69, 163
 - on mother-to-child transmission of HIV, 113, 125
 - Reference Group on Estimates, Modelling and Projections, 39
 - resource allocation modeling and, 179, 187
 - surveillance and, 38
 - United States
 - antibiotic use in, 438, 441
 - antimicrobial resistance in, 439
 - cardiovascular disease in, 52
 - diabetes mellitus in, 54
 - dyslipidemia in, 55, 56
 - hepatitis treatment in, 407
 - HIV/AIDS in
 - diabetes mellitus comorbidity, 54
 - dyslipidemia comorbidity, 56
 - female reproductive health and, 51
 - key populations, 36–37
 - linkage to care and treatment, 76
 - localized intervention programs, 163
 - men who have sex with men (MSM), 163
 - regional microepidemics, 36, 37*m*
 - treatment as prevention (TasP), 95, 97
 - HPV vaccinations in, 49
 - infertility treatment in, 51
 - influenza vaccinations in, 440
 - malaria control and elimination in, 317, 352
 - vector control, 326
 - sexually transmitted infections in, 203, 208
 - behavioral change interventions, 207
 - burden of, 206–7
 - microbicide interventions, 214
 - partner notification, 215
 - structural interventions, 217
 - tuberculosis in
 - incidence rates, 236
 - infection control, 259
 - preventive therapy, 257, 258
 - research and development, 276
 - universal public finance (UPF) for tuberculosis treatment, 289–90
 - University of California, San Francisco, 180, 192, 199
 - U.S. Agency for International Development (USAID), 187, 196
 - Uzbekistan, malaria elimination in, 315, 318
- V**
- vaccines and vaccinations
 - antibiotics and antimicrobial resistance, 440–41
 - bacille Calmette–Guérin (BCG) vaccine, 233, 243, 255–56, 278, 279
 - cost-effectiveness of, 20
 - hepatitis, 16, 49, 401, 404–5, 404*f*, 406
 - hepatitis A, 401, 404, 406
 - hepatitis B, 209, 213, 222, 401, 404, 406
 - hepatitis D, 401
 - hepatitis E, 401, 404–5
 - HIV/AIDS, 48–49
 - human papillomavirus (HPV), 48–49, 209, 213, 222
 - influenza, 440
 - malaria, 11, 329, 356–58, 357*f*
 - resource allocation modeling and, 194
 - tuberculosis, 233, 243, 255–56
 - Vanuatu, malaria elimination in, 321*b*, 332
 - Vassall, Anna, 233, 281
 - vector control
 - dengue, 419, 424, 427
 - malaria, 325–27, 349, 358–59, 358*f*
 - neglected tropical diseases (NTDs), 412, 418–19, 418*t*, 421
 - Venezuela. *See* República Bolivariana de Venezuela
 - Verguet, S., 290
 - Vickerman, P., 220, 222
 - Vietnam
 - antibiotic use in, 438
 - antimicrobial resistance in, 439
 - dengue in, 414–15
 - HIV/AIDS in
 - 90-90-90 targets and, 34
 - localized intervention programs, 165, 166*m*
 - treatment as prevention (TasP), 95, 97
 - malaria elimination in, 321*b*, 323
 - sexually transmitted infections in, 217
 - syphilis in, 203
 - tuberculosis in
 - community-based care, 268
 - hospital-based care in, 264
 - viral hepatitis. *See* hepatitis
 - visceral leishmaniasis
 - cost-effectiveness of interventions, 374, 422
 - incidence rates, 19, 415
 - mortality rates, 416
 - treatment interventions, 18, 423
 - Volchenkov, Grigory, 233
 - voluntary male medical circumcision (VMMC)
 - HIV/AIDS interventions and, 7, 97, 144–45, 164

resource allocation modeling and, 189–90,
194, 196, 198
sexually transmitted infection prevention, 209, 210
vulvar intraepithelial neoplasia, 51

W

Wagner, B. G., 95
Walensky, R. P., 97
Walker, D., 146
warfarin, 253
Wasserheit, J. N., 210
Weller, S. C., 144
Wells, Tim, 347
West Africa. *See also specific countries*
hepatitis in
incidence rates, 16
mortality rates, 401
prevalence, 401
HIV/AIDS in, 161
Wetmore, C. M., 210
What Works Reviews (WWR), 193–94, 193f, 195f
White, Richard, 233
WHO. *See* World Health Organization
Wiedeman, Danielle, 29
Wiktor, Stefan Z., 401
Wilson, David, 95, 157
Wilson, Douglas, 233
Wolf, H., 333
women. *See also* sex workers
family planning and, 50
febrile illness and, 368, 368t
hepatitis vaccinations for, 404
infertility and, 50–51
malaria among, 322, 348
maternal screening for sexually transmitted
infections, 222
reproductive health, 45–46, 50–51
syphilis among, 208, 222
tuberculosis among, 253
World Bank, 170, 180, 190
World Health Assembly, 16, 24n6, 315, 318,
349, 412, 439
World Health Organization (WHO)
on cervical cancer screening, 49
Clinical Staging and Disease Classification
System, 24n1
on febrile illness, 366, 385, 398
Global Health Estimates, 31
Guidelines Group on Couples HIV Testing and
Counseling, 102, 102b
on hepatitis, 407

on hepatitis vaccinations, 49
HIV/AIDS treatment guidelines, 30, 31, 68, 69, 75,
77, 79, 96, 102–3, 138, 163
HIV prevention cascade, 140
on HPV vaccinations, 48–49
Integrated Management of Adolescent and
Adult Illness (IMAI), 371, 375
International Health Regulations, 1
on malaria, 11–12, 315, 349
malaria treatment guidelines, 371
on mother-to-child transmission of HIV, 113
on neglected tropical diseases, 16
NTD Roadmap, 412, 416, 418, 423, 427
resource allocation modeling and, 190, 199
on sexually transmitted infections, burden of, 7
on syphilis incidence rates, 117, 122
on treatment as prevention (TasP), 164
on tuberculosis, 10, 233, 235, 242b, 269b, 280
vector management strategy, 418
World Organisation for Animal Health, 440b
Wu, Y., 333
WWR (What Works Reviews), 193–94, 193f, 195f

X

Xpert MTB/RIF test, 250, 261–62, 281–82, 292

Y

Yadav, Prashant, 233
yaws
cost-effectiveness of interventions, 422
treatment interventions, 2, 18, 420, 423, 427
Ying, R., 100
Yuen, C. M., 263

Z

Zambia
HIV/AIDS in
adherence to treatment, 79, 80
linkage to care and treatment, 75
mother-to-child transmission, 130
prevention interventions, 148
surveillance, 38
testing services, 68
treatment as prevention (TasP), 95, 97, 101, 104b
malaria control and elimination in, 321b, 352
syphilis in, 129, 130
tuberculosis in
community-based care, 266
diagnosis, 261, 263
Zanzibar, malaria elimination in
cost-effectiveness of interventions, 332

- financing of interventions, 335*b*
- Zika virus, 2, 8, 18, 22, 421
- Zimbabwe
 - HIV/AIDS in
 - adherence to treatment, 79, 80
 - cardiovascular disease comorbidity, 53
 - incidence rates, 35, 35*f*, 138
 - linkage to care and treatment, 75
 - prevention interventions, 146, 147*f*, 149
 - retention in care, 77
 - surveillance, 38
 - testing services, 68
 - malaria elimination in, 321*b*
 - sexually transmitted infections in, 214
 - tuberculosis in, 272
- Zwerling, A., 284

ECO-AUDIT

Environmental Benefits Statement

The World Bank Group is committed to reducing its environmental footprint. In support of this commitment, we leverage electronic publishing options and print-on-demand technology, which is located in regional hubs worldwide. Together, these initiatives enable print runs to be lowered and shipping distances decreased, resulting in reduced paper consumption, chemical use, greenhouse gas emissions, and waste.

We follow the recommended standards for paper use set by the Green Press Initiative. The majority of our books are printed on Forest Stewardship Council (FSC)-certified paper, with nearly all containing 50–100 percent recycled content. The recycled fiber in our book paper is either unbleached or bleached using totally chlorine-free (TCF), processed chlorine-free (PCF), or enhanced elemental chlorine-free (EECF) processes.

More information about the Bank's environmental philosophy can be found at <http://www.worldbank.org/corporateresponsibility>.

